REFERENCIAS BIBLIOGRÁFICAS DEL CAPÍTULO 34

1. Spangler WL, Culbertson MR: Prevalence, type, and importance of splenic diseases in dogs:
1,480 cases (1985-1989), J Am Vet Med Assoc 200:829–834, 1992.

2. Prymak C, McKee LJ, Goldschmidt MH, et al.: Epidemiologic, clinical, pathologic, and prognostic
characteristics of splenic hemangiosarcoma and splenic hematoma in dogs: 217 cases (1985), J
Am Vet Med Assoc 193:706–712, 1988.

3. Brown NO, Patnaik AK, MacEwen EG: Canine hemangiosarcoma: retrospective analysis of 104
cases, J Am Vet Med Assoc 186:56–58, 1985.

4. Clifford CA, de Lorimier LP: Hemangiosarcoma. In Ettinger SJ, Feldman EC, Cote E, editors:
Textbook of veterinary internal medicine, ed 8, St. Louis, 2017, Elsevier, pp 2093–2102.

5. Spangler WL, Kass PH: Pathologic factors affecting postsplenectomy survival in dogs, J Vet
Intern Med 11:166–171, 1997.

6. Schultheiss PC: A retrospective study of visceral and nonvisceral hemangiosarcoma and

hemangiomas in domestic animals, J Vet Diagn Invest 16:522–526, 2004.

7. Yoon HY, Kang HM, Lee MY: Primary cranial mediastinal hemangiosarcoma in a young dog, Ir
Vet J 67(15), 2014.

8. KA Powers BE, Withrow SJ, et al.: Splenomegaly in dogs: predictors of neoplasia and survival
after splenectomy, J Vet Intern Med 3:160–166, 1989.

9. Tamburini BA, Trapp S, Phang TL, et al.: Gene expression profiles of sporadic canine
hemangiosarcoma are uniquely associated with breed, PLoS One 4:e5549, 2009.

10. Gamlem H, Nordstoga K, Arnesen K: Canine vascular neoplasia–a population-based

clinicopathologic study of 439 tumours and tumour-like lesions in 420 dogs, APMIS (Suppl)41–54,
2008.

11. Johannes CM, Henry CJ, Turnquist SE, et al.: Hemangiosarcoma in cats: 53 cases (1992-
2002), J Am Vet Med Assoc 231:1851–1856, 2007.

12. Hargis AM, Ihrke PJ, Spangler QL, et al.: A retrospective clinicopathologic study of 212 dogs
with cutaneous hemangiomas and hemangiosarcomas, Vet Pathol 29:316–328, 1992.

13. Nikula KJ, Benjamin SA, Angleton GM, et al.: Ultraviolet radiation, solar dermatosis, and
cutaneous neoplasia in Beagle dogs, Radiat Res 129:11–18, 1992.

14. Szivek A, Burns RE, Gericota B, et al.: Clinical outcome in 94 cases of dermal
haemangiosarcoma in dogs treated with surgical excision: 1993-2007, Vet Comp Oncol 10:65–73,
2012.

15. Ware WA, Hopper DL: Cardiac tumors in dogs: 1982-1995, J Vet Intern Med 13:95–103, 1999.

16. Torres de la Riva G, Hart BL, Farver TB, et al.: Neutering dogs: effects on joint disorders and
cancers in golden retrievers, PLOS One 8:e55937, 2013.

17. Lamerato-Kozicki AR, Helm KM, Jubala CM, et al.: Canine hemangiosarcoma originates from
hematopoietic precursors with potential for endothelial differentiation, Exp Hematol 34:870–878,
2006.

18. Fosmire SP, Dickerson EB, Scott AM, et al.: Canine malignant hemangiosarcoma as a model of
primitive angiogenic endothelium, Lab Invest 84:562–572, 2004.
19. Gorden BH, Kim JH, Sarber AL, et al.: Identification of three molecular and functional subtypes
in canine hemangiosarcoma through gene expression profiling and progenitor cell characterization,
Am J Pathol 184:985–995, 2014.

20. Tamburini BA, Phang TL, Fosmire SP, et al.: Gene expression profiling identifies inflammation
and angiogenesis as distinguishing features of canine hemangiosarcoma, BMC Canc 10:619, 2010.

21. Thomas R, Borst L, Rotroff D, et al.: Genomic profiling reveals extensive heterogeneity in
somatic DNA copy number aberrations of canine hemangiosarcoma, Chrom Res 22:305–319,
2014.

22. Naka N, Tomita Y, Nakanashi H, et al.: Mutations of p53 tumorsuppressor gene in

angiosarcoma, Int J Cancer 71:952–955, 1997.

23. Arbiser JL, Moses MA, Fernandez CA, et al.: Oncogenic H-ras stimulates tumor angiogenesis
by two distinct pathways, Proc Natl Acad Sci USA 94:861–866, 1997.

24. Garcia JM, Gonzalez R, Silva JM, et al.: Mutational status of K-ras and TP53 genes in primary
sarcomas of the heart, Br J Cancer 82:1183–1185, 2000.

25. Mayr B, Zwetkoff S, Schaffner G, et al.: Tumour suppressor gene p53 mutation in a case of
haemangiosarcoma of a dog, Acta Vet Hung 50:157–160, 2002.

26. Yonemaru K, Sakai H, Murakami M, et al.: The significance of p53 and retinoblastoma pathways
in canine hemangiosarcoma, J Vet Med Sci 69:271–278, 2007.

27. Dickerson EB, Thomas R, Fosmire P, et al.: Mutations of phosphatase and tensin homolog
deleted from chromosome 10 in canine hemangiosarcoma, Vet Pathol 42:618–632, 2005.

28. Murakami M, Sakai H, Kodama A, et al.: Expression of the antiapoptotic factors Bcl-2 and
survivin in canine vascular tumours, J Comp Pathol 139:1–7, 2008.

29. Yonemaru K, Sakai H, Murakami M, et al.: Expression of vascular endothelial growth factor,
basic fibroblast growth factor, and their receptors (flt-1, flk-1, and flg-1) in canine vascular tumors,
Vet Pathol 43:971–980, 2006.

30. Dickerson EB, Marley K, Edris W, et al.: Imatinib and dasatinib inhibit hemangiosarcoma and
implicate PDGFR-β and Src in tumor growth, Transl Oncol 6:158–168, 2013.

31. Kodama A, Sakai H, Matsuura S, et al.: Establishment of canine hemangiosarcoma xenograft

models expressing endothelial growth factors, their receptors, and angiogenesis-associated
homeobox genes, BMC Cancer 14:363, 2009.

32. Clifford CA, Hughes D, Beal MW, et al.: Plasma vascular endotelial growth factor concentrations
in healthy dogs and dogs with hemangiosarcoma, J Vet Intern Med 15:131–135, 2001.

33. Fukumoto S, Miyasho T, Hanazono K, et al.: Big endothelin-1 as a tumour marker for canine
hemangiosarcoma, Vet J 204:269–274, 2015.

34. Eberle N, von Babo V, Nolte I, et al.: Splenic masses in dogs. Part 1: epidemiologic, clinical
characteristics as well as histopathologic diagnosis in 249 cases (2000-2011), Tierarztl Prax Ausg K
Kleintiere Heimtiere 40:250–260, 2012.

35. Aronsohn M: Cardiac hemangiosarcoma in the dog: a review of 38 cases, J Am Vet Med Assoc
187:922–926, 1985.
36. Yamamoto S, Hoshi K, Hirakawa A: Epidemiological, clinical and pathological features of
primary cardiac hemangiosarcoma in dogs: a review of 51 cases, J Vet Med Sci 75:1433–1441,
2013.

37. Mullin CM, Arkans MA, Sammarco CD, et al.: Doxorubicin chemotherapy for presumptive
cardiac hemangiosarcoma in dogs, Vet Comp Oncol 14:e171–e183, 2016.

38. Ward H, Fox LE, Calderwood-Mays MB, et al.: Cutaneous hemangiosarcoma in 25 dogs: a
retrospective study, J Vet Intern Med 8:345–348, 1994.

39. Aupperle H, Marz I, Ellenberger C, et al.: Primary and secondary heart tumours in dogs and
cats, J Comp Pathol 136:18–26, 2007.

40. Locke JE, Barber LG: Comparative aspects and clinical outcomes of canine renal
hemangiosarcoma, J Vet Intern Med 20:962–967, 2006.

41. Liptak JM, Dernell WS, Ehrhart EJ, et al.: Retroperitoneal sarcomas in dogs: 14 cases (1992-
2002), J Am Vet Med Assoc 224:1471–1477, 2004.

42. Giuffrida MA, Bacon NJ, KaMTSock DA: Use of routine histopathology and factor VIII-related
antigen/von Willebrand factor immunohistochemistry to differentiate primary hemangiosarcoma of
bone from telangiectatic osteosarcoma in 54 dogs, Vet Comp Oncol 15:1232–1239, 2017.

43. Deleted in proof.

44. Dennis MM, Ehrhart N, Duncan CG, et al.: Frequency of and risk factors associated with lingual
lesions in dogs: 1,196 cases (1995- 2004), J Am Vet Med Assoc 228:1533–1537, 2006.

45. Fujita M, Takaishi Y, Yasuda D, et al.: Intranasal hemangiosarcoma in a dog, J Vet Med Sci
70:525–528, 2008.

46. Pirie CG, Knollinger AM, Thomas CB, et al.: Canine conjunctival hemangioma and
hemangiosarcoma: a retrospective evaluation of 108 cases (1989-2004), Vet Ophthalmol 9:215–
226, 2006.

47. Liptak JM, Dernell WS, Withrow SJ: Haemangiosarcoma of the urinary bladder in a dog, Aust
Vet J 82:215–217, 2004.

48. Wobeser BK, Kidney BA, Powers BE, et al.: Diagnoses and clinical outcomes associated with
surgically amputated canine digits submitted to multiple veterinary diagnostic laboratories, Vet
Pathol 44:355–361, 2007.

49. Pintar J, Breitschwerdt EB, Hardie EM, et al.: Acute nontraumatic hemoabdomen in the dog: a
retrospective analysis of 39 cases (1987-2001), J Am Anim Hosp Assoc 39:518–522, 2003.

50. Hammond TN, Pesillo-Crosby SA: Prevalence of hemangiosarcoma in anemic dogs with a
splenic mass and hemoperitoneum requiring a transfusion: 71 cases (2003-2005), J Am Vet Med
Assoc 232:553–558, 2008.

51. Aronsohn MG, Dubiel B, Roberts B, et al.: Prognosis for acute nontraumatic hemoperitoneum in
the dog: a retrospective analysis of 60 cases (2003-2006), J Am Anim Hosp Assoc 45:72–77, 2009.

52. Mallinckrodt MJ, Gottfried SD: Mass-to-splenic volume ratio and splenic weight as a percentage
of body weight in dogs with malignant and benign splenic masses: 65 cases (2007–2008), J Am Vet
Med Assoc 239:1325–1327, 2011.

53. Boston SE, Higginson G, Monteith G: Concurrent splenic and right atrial mass at presentation in
dogs with HSA: a retrospective study, J Am Anim Hosp Assoc 47:336–341, 2011.
54. Snyder JM, Lipitz L, Skorupski KA, et al.: Secondary intracranial neoplasia in the dog: 177
cases (1986-2003), J Vet Intern Med 22:172–177, 2008.

55. Scavelli TD, Patnaik AK, Mehlhaff CJ, et al.: Hemangiosarcoma in the cat: retrospective
evaluation of 31 surgical cases, J Am Vet Med Assoc 187:817–819, 1985.

56. Miller MA, Ramos JA, Kreeger JM: Cutaneous vascular neoplasia in 15 cats: clinical,
morphologic, and immunohistochemical studies, Vet Pathol 29:329–336, 1992.

57. Kraje AC, Mears EA, Hahn KA, et al.: Unusual metastatic behavior and clinicopathologic
findings in eight cats with cutaneous or visceral hemangiosarcoma, J Am Vet Med Assoc 214:670–
672, 1999.

58. McAbee KP, Ludwig LL, Bergman PJ, et al.: Feline cutaneous hemangiosarcoma: a
retrospective study of 18 cases (1998-2003), J Am Anim Hosp Assoc 41:110–116, 2005.

59. Culp WT, Drobatz KJ, Glassman MM, et al.: Feline visceral hemangiosarcoma, J Vet Intern Med
22:148–152, 2008.

60. Sharpe A, Cannon MJ, Lucke VM, et al.: Intestinal haemangiosarcoma in the cat: clinical and
pathological features of four cases, J Small Anim Pract 41:411–415, 2000.

61. Pirie CG, Dubielzig RR: Feline conjunctival hemangioma and hemangiosarcoma: a
retrospective evaluation of eight cases (1993- 2004), Vet Ophthalmol 9:227–231, 2006.

62. Wobeser BK, Kidney BA, Powers BE, et al.: Diagnoses and clinical outcomes associated with
surgically amputated feline digits submitted to multiple veterinary diagnostic laboratories, Vet Pathol
44:362–365, 2007.

63. Newkirk KM, Rohrbach BW: A retrospective study of eyelid tumors from 43 cats, Vet Pathol
46:916–927, 2009.

64. von Beust BR, Suter MM, Summers BA: Factor VIII-related antigen in canine endothelial
neoplasms: an immunohistochemical study, Vet Pathol 25:251–255, 1988.

65. Ferrer L, Fondevila D, Rabanal RM, et al.: Immunohistochemical detection of CD31 antigen in
normal and neoplastic canine endothelial cells, J Comp Pathol 112:319–326, 1995.

66. Bulakowski EJ, Philibert JC, Siegal S, et al.: Evaluation of outcome associated with
subcutaneous and intramuscular hemangiosarcoma treated with adjuvant doxorubicin in dogs: 21
cases (2001-2006), J Am Vet Med Assoc 233:122–128, 2008.

67. Wiley JL, Rook KA, Clifford CA, et al.: Efficacy of doxorubicinbased chemotherapy for non-
resectable canine subcutaneous haemangiosarcoma, Vet Comp Oncol 8:221–233, 2010.

68. Shiu KB, Flory AB, Anderson CL, et al.: Predictors of outcome in dogs with subcutaneous or
intramuscular hemangiosarcoma, J Am Vet Med Assoc 238:472–479, 2011.

69. Culp WT, Weisse C, Kellogg ME, et al.: Spontaneous hemoperitoneum in cats: 65 cases (1994-
2006), J Am Med Assoc 236:978–982, 2010.

70. Childress MO: Hematologic abnormalities in the small animal cancer patient, Vet Clin North Am
Small Anim Pract 42:123–155, 2012.

71. Warry E, Bohn A, Emanuelli, et al.: Disease distribution in canine patients with acanthocytosis:
123 cases, Vet Clin Pathol 42:465– 470, 2013.
72. Hargis AM, Feldman BF: Evaluation of hemostatic defects secondary to vascular tumors in
dogs: 11 cases (1983-1988), J Am Vet Med Assoc 198:891–894, 1991.

73. Maruyama H, Miura T, Sakai M, et al.: The incidence of disseminated intravascular coagulation
in dogs with malignant tumor, J Vet Med Sci 66:573–575, 2004.

74. Wrigley RH, Park RD, Konde LJ, et al.: Ultrasonographic features of splenic hemangiosarcoma
in dogs: 18 cases (1980-1986), J Am Vet Med Assoc 192:1113–1117, 1988.

75. Cuccovillo A, Lamb CR: Cellular features of sonographic target lesions of the liver and spleen in
21 dogs and a cat, Vet Radiol Ultrasound 43:275–278, 2002.

76. O’Brien RT: Improved detection of metastatic hepatic hemangiosarcoma nodules with contrast
ultrasound in three dogs, Vet Rad Ultrasound 48:146–148, 2007.

77. Ohlerth S, Dennler M, Ruefli E, et al.: Contrast harmonic imaging characterization of canine
splenic lesions, J Vet Intern Med 22:1095–1102, 2008.

78. Holt D, Van Winkle T, Schelling C, et al.: Correlation between thoracic radiographs and
postmortem findings in dogs with hemangiosarcoma: 77 cases (1984-1989), J Am Vet Med Assoc
200:1535– 1539, 1992

79. Stafford Johnson M, Martin M, Binns S, et al.: A retrospective study of clinical findings,
treatment, and outcome in 143 dogs with pericardial effusion, J Small Anim Pract 45:546–552,
2004.

80. MacDonald KA, Cagney O, Magne ML: Echocardiographic and clinicopathologic

characterization of pericardial effusion in dogs: 107 cases (1995-2006), J Am Vet Med Assoc
235:1456–1461, 2009.

81. Ratterree W, Gieger T, Pariaut R, et al.: Value of echocardiography and electrocardiography as

screening tools prior to doxorubicin administration, J Am Anim Hosp Assoc 48:89–96, 2012.

82. Wendelburg KM, O’Toole TE, McCobb E, et al.: Risk factors for perioperative death in dogs
undergoing splenectomy for splenic masses: 539 cases (2001-2012), J Am Vet Med Assoc
245:1382– 1390, 2014.

83. LeBlanc AK, Daniel GB: Advanced imaging for veterinary cancer patients, Vet Clin Small Anim
37:1059–1077, 2007.

84. Clifford CA, Pretorius ES, Weisse C, et al.: Magnetic resonance imaging of focal splenic and
hepatic lesions in the dog, J Vet Intern Med 18:330–338, 2004.

85. Fife WD, Samii VF, Drost WT, et al.: Comparison between malignant and nonmalignant splenic
masses in dogs using contrast-enhanced computed tomography, Vet Radiol Ultrasound 45:289–
297, 2004.

86. Armbrust LJ, Biller DS, Bamford A, et al.: Comparison of threeview thoracic radiography and
computed tomography for detection of pulmonary nodules in dogs with neoplasia, J Am Vet Med
Assoc 240:1088–1094, 2012.

87. Shaw SP, Rozanski EA, Rush JE: Cardiac troponins I and T in dogs with pericardial effusion, J
Vet Intern Med 18:322–324, 2004.

88. Chun R, Kellihan HB, Henik RA, et al.: Comparison of plasma cardiac troponin I concentrations
among dogs with cardiac hemangiosarcoma, noncardiac hemangiosarcoma, other neoplasms, and
pericardial effusion of nonhemangiosarcoma origin, J Am Vet Med Assoc 237:806–811, 2010.
89. Duda LE, Sorenmo KU: Urine basic fibroblast growth factor in canine hemangiosarcoma. In
Proceedings of the Veterinary Cancer Society Annual Conference, 73, 1997, Chicago.

90. Thamm DH, Kamstock DA, Sharp CR, et al.: Elevated serum thymidine kinase activity in canine
splenic hemangiosarcoma, Vet Comp Oncol 10:292–302, 2012.

91. Kirby GM, Mackay A, Grant A, et al.: Concentration of lipocalin region of collagen XXVII alpha I
in the serum of dogs with hemangiosarcoma, J Vet Intern Med 25:497–503, 2011.

92. Bertazzolo W, Dell’Orco M, Bonfanti U, et al.: Canine angiosarcoma: cytologic, histologic, and
immunohistochemical correlations, Vet Clin Pathol 34:28–34, 2005.

93. Clendaniel DC, Sivacolundhu RK, Sorenmo KU, et al.: Association between macroscopic
appearance of liver lesions and liver histology in dogs with splenic hemangiosarcoma: 70 cases
(2004- 2009), J Am Anim Hosp 50:e6–e10, 2014.

94. Weisse C, Soares N, Beal MW, et al.: Survival times in dogs with right atrial hemangiosarcoma
treated by means of surgical resection with or without adjuvant chemotherapy: 23 cases (1986-
2000), J Am Vet Med Assoc 226:575–579, 2005.

95. Ployart S, Libermann S, Doran I, et al.: Thoracoscopic resection of right auricular masses in
dogs: 9 cases (2003–2011), J Am Vet Med Assoc 242:237–241, 2013.

96. Morges M, Worley DR, Withrow SJ, et al.: Pericardial free patch grafting as a rescue technique
in surgical management of right atrial HSA, J Am Anim Hosp Assoc 47:224–228, 2011.

97. Verbeke F, Binst D, Stegen L: Total venous inflow occlusion and pericardial auto-graft
reconstruction for right atrial hemangiosarcoma resection in a dog, Can Vet J 53:1114–1118, 2012.

98. Case BL, Maxwell M, Aman A, et al.: Outcome evaluation of a thoracoscopic pericardial window
procedure or subtotal pericardectomy via thoracotomy for the treatment of pericardial effusion in
dogs, J Am Vet Med Assoc 242:493–498, 2013.

99. Ogilvie GK, Powers BE, Mallinckrodt CH, et al.: Surgery and doxorubicin in dogs with
hemangiosarcoma, J Vet Intern Med 10:379–384, 1996.

100. Sorenmo KU, Baez JL, Clifford CA, et al.: Efficacy and toxicity of a dose-intensified doxorubicin
protocol in canine hemangiosarcoma, J Vet Intern Med 18:209–213, 2004.

101. Sorenmo KU, Jeglum KA, Helfand SC: Chemotherapy of canine hemangiosarcoma with
doxorubicin and cyclophosphamide, J Vet Intern Med 7:370–376, 1993.

102. Sorenmo K, Duda L, Barber L, et al.: Canine hemangiosarcoma treated with standard
chemotherapy and minocycline, J Vet Intern Med 14:395–398, 2000.

103. Hammer AS, Couto CG, Filppi J, et al.: Efficacy and toxicity of VAC chemotherapy (vincristine,
doxorubicin, and cyclophosphamide) in dogs with hemangiosarcoma, J Vet Intern Med 5:160–166,
1991.

104. Dervisis NG, Dominguez PA, Newman RG, et al.: Treatment with DAV for advanced-stage
hemangiosarcoma in dogs, J Am Anim Hosp Assoc 46:170–178, 2011.

105. Payne SE, Rassnick KM, Northrup NC, et al.: Treatment of vascular and soft-tissue sarcomas
in dogs using an alternating protocol of ifosfamide and doxorubicin, Vet Comp Oncol 1:171–179,
2003.
106. Finotello R, Stefanello D, Zini E, et al.: Comparison of doxorubicin-cyclophosphamide with
doxorubicin-dacarbazine for the adjuvant treatment of canine hemangiosarcoma, Vet Comp Oncol
15:25–35, 2017.

107. Kahn SA, Mullin CM, de Lorimier LP, et al.: Doxorubicin and deracoxib adjuvant therapy for
canine splenic hemangiosarcoma: a pilot study, Can Vet J 54:237–242, 2013.

108. Rassnick KM, Frimberger AE, Wood CA, et al.: Evaluation of ifosfamide for treatment of
various canine neoplasms, J Vet Intern Med 14:271–276, 2000.

109. Teske E, Rutteman GR, Kirpenstein J, et al.: A randomized controlled study into the efficacy
and toxicity of pegylated liposome encapsulated doxorubicin as an adjuvant therapy in dogs with
splenic haemangiosarcoma, Vet Comp Oncol 9:283–289, 2011.

110. Sorenmo K, Samluk M, Clifford C, et al.: Clinical and pharmacokinetic characteristics of

intracavitary administration of pegylated liposomal encapsulated doxorubicin in dogs with splenic
hemangiosarcoma, J Vet Intern Med 21:1347–1354, 2007.

111. Kim SE, Liptak JM, Gall TT, et al.: Epirubicin in the adjuvant treatment of splenic
hemangiosarcoma in dogs: 59 cases (1997- 2004), J Am Vet Med Assoc 231:1550–1557, 2007.

112. Biller B: Metronomic chemotherapy in veterinary patients with cancer: rethinking the targets
and strategies of chemotherapy, Vet Clin North Am Small Anim Pract 44:17–829, 2014.

113. Lana S, U’Ren L, Plaza S, et al.: Continuous low-dose oral chemotherapy for adjuvant therapy
of splenic hemangiosarcoma in dogs, J Vet Intern Med 21:764–769, 2007.

114. Finotello R, Henriques J, Sabattini S, et al.: A retrospective analysis of chemotherapy switch

suggests improved outcome in surgically removed, biologically aggressive canine
hemangiosarcoma, Vet Comp Oncol 15:493–503, 2017.

115. Matsuyama A, Poirier VJ, Mantovani F, et al.: Adjuvant doxorubicin with or without metronomic
cyclophosphamide for canine splenic hemangiosarcoma, J Am Anim Hosp Assoc 53:304–312,
2017.

116. Bray, et al.: Thalidomide prolongs survival in dogs with splenic hemangiosarcoma, J Small
Anim Pract 59:85–91, 2017.

117. Tripp CD, Fidel J, Anderson CL, et al.: Tolerability of metronomic administration of lomustine in
dogs with cancer, J Vet Intern Med 25:278–284, 2011.

118. Leach TN, Childress MO, Greene SN, et al.: Prospective trial of metronomic chlorambucil
chemotherapy in dogs with naturally occurring cancer, Vet Comp Oncol 10:102–112, 2011.

119. Kisseberth WC, Vail DM, Yaissle J, et al.: Phase I clinical evaluation of carboplatin in tumor-
bearing cats: a Veterinary Cooperative Oncology Group study, J Vet Intern Med 22:83–88, 2008.

120. U’Ren LW, Biller BJ, Elmslie RE, et al.: Evaluation of a novel tumor vaccine in dogs with
hemangiosarcoma, J Vet Intern Med 21:113–120, 2007.

121. Vail DM, MacEwen EG, Kurzman ID, et al.: Liposome-encapsulated muramyl tripeptide
phosphatidylethanolamine adjuvant immunotherapy for splenic hemangiosarcoma in the dog: a
randomized multi-institutional clinical trial, Clin Cancer Res 1:1165– 1170, 1995.

122. Hillers KR, Lana SE, Fuller CR, et al.: Effects of palliative radiation therapy on nonsplenic
hemangiosarcoma in dogs, J Am Anim Hosp Assoc 43:187–192, 2007.
123. Nolan MW, Arkans MM, LaVine, et al.: Pilot study to determine the feasibility of radiation
therapy for dogs with right atrial masses and hemorrhagic pericardial effusion, J Vet Cardiol
19:132–143, 2017.

124. Lyles SE, Milner RJ, Kow K, et al.: In vitro effects of the tyrosine kinase inhibitor, masitinib
mesylate, on canine hemangiosarcoma cell lines, Vet Comp Oncol 10:223–235, 2012.

125. London C, Mathie T, Stingle N, et al.: Preliminary evidence for biologic activity of toceranib
phosphate (Palladia(®)) in solid tumours, Vet Comp Oncol 10:194–205, 2012.

126. Gardner HL, London CA, Portela RA, et al.: Maintenance therapy with toceranib following
doxorubicin-based chemotherapy for canine splenic hemangiosarcoma, BMC Vet Res 11:131,
2015.

127. Borgatti A, Koopmeiners JS, Sarver AL, et al.: Safe and effective sarcoma therapy through
bispecific targeting of EGFR and uPAR, Mol Cancer Ther 16:956–965, 2017.

128. Wirth KA, Kow K, Salute ME, et al.: In vitro effects of Yunnan Baiyao on canine
hemangiosarcoma cell lines, Vet Comp Oncol 14:281–294, 2016.

129. Egger C, Gibbs D, Wheeler J, et al.: Effect of oral administration of Yunnan Baiyao on
periprocedural hemorrhage in dogs undergoing nasal biopsy: a prospective, randomized, double-
blinded controlled study, Am Jour Trad Chin Vet Med 11:27–36, 2016.

130. Frederick J, Boysen S, Wagg C, Chalhoub S: The effects of oral administration of Yunnan
Baiyao on blood coagulation in Beagle dogs as measured by kaolin-activated thromboelastography
and buccal mucosal bleeding times, Can J Vet Res 81:41–45, 2017.

131. Murphy LA, Panek CM, Bianco D, Nakamura RK: Use of Yunnan Baiyao and epsilon
aminocaproic acid in dogs with right atrial masses and pericardial effusion, J Vet Emerg Crit Care
27:121–126, 2017.

132. Brown DC, Reetz J: Single agent polysaccharopeptide delays metastases and improves
survival in naturally occurring hemangiosarcoma, Evid Based Comp Alt Med 2012, 2012. 3284301.

133. Alvarez FJ, Hosoya K, Lara-Garcia A, et al.: VAC protocol for treatment of dogs with stage III
hemangiosarcoma, J Am Anim Hosp Assoc 49:370–377, 2013.

134. Gordon SS, McClaran JK, Bergman PJ, et al.: Outcome following splenectomy in cats, J Fel
Med Surg 12:256–261, 2010.

135. Simonart T, Heenen M: Radiation-induced angiosarcomas, Dermatology 209:175–176, 2004.

136. Parker GA, Casey HW: Thymomas in domestic animals, Vet Pathol 13:353–364, 1976.

137. Aronsohn M: Canine thymomas, Vet Clin North Am 15:755–776, 1985.

138. Robat CS, Cesario L, Gaeta R, et al.: Clinical features, treatment options, and outcome in
dogs with thymoma: 116 cases (1990- 2010), J Am Vet Med Assoc 243:1448–1454, 2013.

139. Zitz JC, Birchard SJ, Couto GC, et al.: Results of excision of thymomas in cats and dogs: 20
cases (1984-2005), J Am Vet Med Assoc 232:1186–1192, 2008.

140. Aronsohn MG, Schunk KL, Carpenter JL, et al.: Clinical and pathologic features of thymomas
in 15 dogs, J Am Vet Med Assoc 184:1355–1362, 1984.

141. Atwater SW, Powers BE, Park RD, et al.: Canine thymomas: 23 cases (1980-1991), J Am Vet
Med Assoc 205:1007–1013, 1994.
142. Patnaik AK, Lieberman PH, Erlandson RA, et al.: Feline cystic thymomas: a clinicopathologic,
immunohistologic, and electron microscopic study of 14 cases, J Feline Med Surg 5:27–35, 2003.

143. Carpenter JL, Valentine BA: Brief communications and case reports: squamous cell carcinoma
arising in two feline thymomas, Vet Pathol 29:541–543, 1992.

144. Vilafranca M, Font A: Thymolipoma in a cat, J Feline Med and Surg 7:125–127, 2005.

145. Robinson WC, Cantwell HD, Crawley RR, et al.: Invasive thymoma in a dog: a case report, J
Am Anim Hosp Assoc 13:95–97, 1977.

146. Bella JR, Stiff ME, Russel RG: Thymoma in the dog: two case reports and review of 20
additional cases, J Am Vet Med Assoc 183:306–311, 1983.

147. Day MJ: Review of thymic pathology in 30 cats and 36 dogs, J Sm Anim Pract 38:393–403,
1997.

148. Bell FW: Neoplastic diseases of the thorax, Vet Clin of North Am Sm Anim Pract 17:387–409,
1987.

149. Darke PG: Myasthenia gravis, thymoma, and myositis in a dog, Vet Rec 97:392–395, 1975.

150. Carpenter JL, Holzworth J: Thymoma in 11 cats, J Am Vet Med Assoc 181:248–251, 1982.

151. Turek MM: Cutaneous paraneoplastic syndromes in dogs and cats: a review of the literature,
Vet Dermatol 14:279–296, 2003.

152. Rottenberg S, von Tscharner C, Roosje PJ: Thymoma-associated exfoliative dermatitis in cats,
Vet Pathol 41:429–433, 2004.

153. Uchida K, Awamura Y, Nakamura T, et al.: Thymoma and multiple thymic cysts in a dog with
acquired myasthenia gravis, J Vet Med Sci 64:637–640, 2002.

154. Stenner VJ, Parry BW, Holloway SA: Acquired myasthenia gravis associated with a non-
invasive thymic carcinoma in a dog, Aust Vet J 81:543–546, 2003.

155. Paciello O, Maiolino P, Navas L, et al.: Acquired canine myasthenia gravis associated with
thymoma: histological features and immunolocalization of HLA type II and IgG, Vet Res Commun
27(Suppl 1):715–718, 2003.

156. Moffet AC: Metastatic thymomas and acquired generalized myasthenia gravis in a beagle, Can
Vet J 48:91–93, 2007.

157. Singh A, Boston SE, Poma R: Thymoma-associated exfoliative dermatitis with post-
thymectomy myasthenia gravis in a cat, Can Vet J 51:757–760, 2010.

158. Foley P, Shaw D, Runyon C: Serum parathyroid hormone-related protein concentration in a

dog with thymomas and persistent hypercalcemia, Can Vet J 41:867–870, 2000.

159. Theilen GH, Madewell BR: Tumors of the respiratory tract and thorax, ed 1, Veterinary cancer
medicine, Philadelphia, 1979, Lea & Febiger, pp 535–566.

160. Harris CL, Klausner JS, Caywood DD, et al.: Hypercalcemia in a dog with thymomas, J Am
Anim Hosp Assoc 27:281–284, 1991.

161. Bolliger AP, Graham PA, Richard V, et al.: Detection of parathyroid hormone-related protein in
cats with humoral hipercalcemia of malignancy, Vet Clin Pathol 31:3–8, 2002.
162. Marconato L, Stefanello D, Valenti P, et al.: Predictors of longterm survival in dogs with high-
grade multicentric lymphoma, J Am Vet Med Assoc 238:480–485, 2011.

163. Patterson MME, Marolf A: Sonographic characteristics of thymoma compared with mediastinal
lymphoma, J Am Anim Hosp Assoc 50:409–413, 2014.

164. Reickle JK, Wisner ER: Non-cardiac thoracic ultrasound in 75 feline and canine patients, Vet
Radiol and Ultrasound 41:154–162, 2000.

165. Larson MM: Ultrasound of the thorax (non-cardiac), Vet Clin of North Am 39:733–745, 2009.

166. Gashen L, Kircher P, Hoffman G, et al.: Endoscopic ultrasound for the diagnosis of
intrathoracic lesions in two dogs, Vet Radiol Ultrasound 44:292–299, 2003.

167. Rae CA, Jacobs RM, Couto CG: A comparison between the cytological and histological
characteristics in thirteen canine and feline thymomas, Can Vet J 30:497–500, 1989.

168. Cowell RL, Tyler RD, Meinkoth JH: The lung parenchyma. In Diagnostic cytology of the dog
and cat, ed 2, St Louis, 1999, Mosby.

169. Lana S, Plaza S, Hampe K, Burnett R, et al.: Diagnosis of mediastinal masses in dogs by flow
cytometry, J Vet Intern Med 20:1161–1165, 2006.

170. Holsworth IG, Kyles AE, Bailiff NL: Use of a jugular vein autograft for reconstruction of the
vena cava in a dog with invasive thymoma and cranial vena cava syndrome, J Am Vet Med Assoc
225:1205–1210, 2004.

171. Yoon J, Feeney DA, Cronk DE, et al.: Computed tomographic evaluation of canine and feline
mediastinal masses in 14 patients, Vet Radiol Ultrasound 45:524–526, 2004.

172. Zekas LJ, Crawford JT, O’Brien RT: Computed tomographicguided biopsy of intrathoracic
lesions in 50 dogs and cats, Vet Radiol Ultrasound 46:200–204, 2005.

173. Hylands R: Veterinary diagnostic imaging, Thymoma, Can Vet J 47:593–596, 2006.

174. Scherrer W, Kyles A, Samii V, et al.: Computed tomographic assessment of vascular invasion
and resectability of mediastinal masses in dogs and cats, NZ Vet J 56:330–333, 2008.

175. Maciver MA, Case JB, Monnet EL, et al.: Video-assisted extirpation of cranial mediastinal
masses in dogs: 18 cases (2009-2014), J Am Vet Med Assoc 250:1283–1290, 2017.

176. Smith AN, Wright JC, Brawner Jr WR, et al.: Radiation therapy in the treatment of canine and
feline thymomas: a retrospective study (1985-1999), J Am Anim Hosp Assoc 37:489–496, 2001.

177. Goto S, Murakami M, Kawabe M, et al.: Hypofractionated radiation therapy in the treatment of
canine thymoma: retrospective study of eight cases, Vet Radiol Ultrasound 58:613–620, 2017.

178. Tong LJ, Hosgood G, Labruyere J, et al.: Marked cytoreduction of a lymphocyte-rich

mediastinal thymoma with neoadjuvant chemotherapy in a cat, JFMS Open Rep
1:2055116915585024, 2015.

179. Moore AS: Chemotherapy for intrathoracic cancer in dogs and cats, Probl Vet Med 4:351–364,
1992.

180. Garneau MS, Price LL, Withrow SJ, et al.: Perioperative mortality and long-term survival in 80
dogs and 32 cats undergoing excision of thymic epithelial tumors, Vet Surg 44:557–564, 2015.

181. Gores BR, Berg J, Carpenter JL: Surgical treatment of thymomas in cats: 12 cases (1987-
1992), J Am Vet Med Assoc 204:1782–1785, 1994.
182. Tomaszek S, Wigle DA, Keshavjee S, et al.: Thymomas: review of current clinical practice,
Ann Thorac Surg 87:1973–1980, 2009.

183. Masaoka A, Monden W, Nakahara K, et al.: Follow-up study of thymomas with special
reference to their clinical stages, Cancer 48:2485–2492, 1981.

184. Ried M, Guth H, Potzger T, et al.: Surgical resection of thymomas still represents the first
choice of treatment, Thorac Cardiovasc Surg 60:145–149, 2012.

185. Cardillo G, Carleo F, Giunti R, et al.: Predictors of survival in patients with locally advanced
thymomas and thymic carcinoma (Masaoka stages III and IVa), Eur J Cardiothorac Surg 37:819–
823, 2010.

186. Ganguly B, Das U, Das AK: Canine transmissible venereal tumour: a review, Vet Comp Onc
14:1–12, 2013.

187. Agnew DW, MacLachlan NJ: Tumors of the genital systems. In Meuten DJ, editor: Tumors in
domestic animals, ed 5, Ames, 2017, Wiley Blackwell, pp 689–722.

188. Schlafer DH, Foster RA: Female genital system. Male genital system. In ed 6, Maxie G, editor:
Pathology of domestic animals, vol. 3. St. Louis, 2016, Elsevier, pp 358–464, 465–510.

189. Cohen D: The canine transmissible venereal tumor: a unique result of tumor progression, Adv
Cancer Res 43:75–112, 1985.

190. Birhan G, Chanie M: A review on canine transmissible venereal tumor: from morphologic to
biochemical and molecular diagnosis, Acad J Anim Dis 4(3):185–195, 2015.

191. Lima CRO, Rabelo RE, Vulcani VAS, et al.: Morphological patterns and malignancy criteria of
transmissible venereal tumor in cytopathological and histopathological exams, Braz J Vet Res Anim
Sci 50(3):238–246, 2013.

192. Mukaratirwa S, Gruys E: Canine transmissible venereal tumour: cytogenetic origin,

immunophenotype, and immunobiology: a review, Vet Q 25:101–111, 2003.

193. Hayes HM, Biggar RJ, Pickle LW, et al.: Canine transmissible venereal tumor: a model for
Kaposi’s sarcoma? Am J Epidemiol 117:108–109, 1983.

194. Mikaelian I, Girard C, Ivascu I: Transmissible venereal tumor: a consequence of sex tourism in
a dog, Can Vet J 39:591, 1998.

195. Rogers KS, Walker MA, Dillon HB: Transmissible venereal tumor: a retrospective study of 29
cases, J Am Anim Hosp Assoc 34:463– 470, 1998.

196. Ojeda J, Mieres M, Soto F, et al.: Computer tomographic imaging in 4 dogs with primary nasal
canine transmissible venereal tumor and differing cellular phenotype, J Vet Intern Med 32:1172–
1177, 2018.

197. Rezaei M, Azizi S, Shahheidaripour S, et al.: Primary oral and nasal transmissible venereal
tumor in a mix-breed dog, Asian Pac J Trop Biomed 6(5):443–445, 2016.

198. Filgueira K, Peixoto G, Fonseca Z: Canine transmissible venereal tumor with multiple
extragenital locations, Acta Sci Vet 41:1–6, 2013.

199. Strakova A, Murchison EP: The changing global distribution and prevalence of canine
transmissible venereal tumour, BMC Vet Res 10, 2014. 168–168.
200. Albanese E, Poli A, Millanta F, et al.: Primary cutaneous extragenital canine transmissible
venereal tumor with Leishmania-laden neoplastic cells: a further suggestion of histiocytic origin? Vet
Dermatol 13:243–246, 2002.

201. Ostrander EA, Davis BW, Ostrander GK: Transmissible tumors: breaking the cancer paradigm,
Trends Genet 32(1):1–15, 2016.

202. Belov K: Contagious cancer: lessons from the devil and the dog, Bioessays 34:285–292, 2012.

203. Murchison EP, Wedge DC, Alexandrov LB, et al.: Transmissible dog cancer genome reveals
the origin and history of an ancient cell lineage, Science 343:437–440, 2014.

204. Belov K: The role of the major histocompatibility complex in the spread of contagious cancers,
Mamm Genome 22:83–90, 2011.

205. Ujvari B, Papenfuss AT, Belov K: Transmissible cancers in an evolutionary context, Bioessays
38:S14–S23, 2016.

206. Rebbeck CA, Thomas R, Breen M, et al.: Origins and evolution of a transmissible cancer,
Evolution 63(9):2340–2349, 2009.

207. Pereira JS, Silva AB, Martins AL, et al.: Immunohistochemical characterization of intraocular
metastasis of a canine transmisible venereal tumor, Vet Ophthalmol 3:43–47, 2000.

208. Lopes PD, dos Santos ACAA, Silva JES: Canine transmissible venereal tumor in the genital
area with subcutaneous metastases in the head - case report, RPCV 110:120–123, 2015.

209. Alkan H, Satilmis F, Alcigir ME, et al.: Clinicopathological evaluation of disseminated

metastases of transmissible venereal tumor in a spayed bitch, Acta Scientiae Veterinariae 45:1–6,
2017.

210. Mozos E, Méndez A, Gómez-Villamandos JC, et al.: Immunohistochemical characterization of

canine transmissible venereal tumor, Vet Path 33:257–263, 1996.

211. Mascarenhas MB, Peixoto PV, Ramadinha RR, et al.: Immunohistochemical study of genital
and extragenital forms of canine transmisible venereal tumor in Brazil, Pesq Vet Bras 34(3):250–
254, 2014.

212. Ajayi OL, Oluwabi M, Ajadi RA, et al.: Cytomorphological, histopathological and
immunohistochemical observations on the histiocytic origin of canine transmissible venereal tumour,
Sokoto J Vet Sci 16(2):10–20, 2018.

213. Gupta K, Sood NK: Pathological and immunohistochemical studies on rare cases of primary
extra-genital transmissible venereal tumours in the mammary gland, Vet Med 57(4):198–206, 2012.

214. Akkoc A, Nak D, Demirer A, et al.: Immunocharacterization of matrix metalloproteinase-2 and

matrix metalloproteinase-9 in canine transmissible venereal tumors, Biotech Histochem 92(2):100–
106, 2017.

215. Kegler K, Habierski A, Hahn K, et al.: Vaginal canine transmisible venereal tumour associated
with intra-tumoural Leishmania spp. Amastigotes in an asymptomatic female dog, J Comp Path
149:156–161, 2013.

216. Decker B, Dais BW, Rimbault M, et al.: Comparison against 186 canid whole-genome
sequences reveals survival strategies of an ancient clonally transmissible canine tumor, Genome
Res 25:1646– 1655, 2015.
217. Strakova A, Leathlobhair MN, Wang G-D: Mitochondrial genetic diversity, selection and
recombination in a canine transmisible cancer, eLife 5:e14552, 2016.

218. Katzir N, Rechavi G, Cohen JB, et al.: “Retroposon” insertion into the cellular oncogene c-myc
in canine transmissible venereal tumor, Proc Natl Acad Sci USA 82:1054–1058, 1985.

219. Choi YK, Kim CJ: Sequence analysis of canine LINE-l elements and p53 gene in canine
transmissible venereal tumor, J Vet Sci 3:285–292, 2002.

220. Fonseca LS, Mota LSLS, Colodel MM, et al.: Spontaneous canine transmissible venereal
tumor: association between different phenotypes and the insertion LINE‐1/c‐myc, Rev Colomb
Cienc Pec 25:402–408, 2012.

221. Strakova A, Murchison EP: The cancer which survived: insights from the genome of an 11 000
year‐old cancer, Curr Opin Genet Dev 30:49–55, 2015.

222. Liao KW, Lin ZY, Pao HN, et al.: Identification of canine transmisible venereal tumor cells
using in situ polymerase chain reaction and the stable sequence of the long interspersed nuclear
element, J Vet Diagn Invest 15:399–406, 2003.

223. Castro KF, Strakova A, Tinucci-Costa M, et al.: Evaluation of a genetic assay for canine
transmissible venereal tumour diagnosis in Brazil, Vet Comp Oncol 15(2):615–618, 2017.

224. Sánchez-Servín A, Martínez S, Cárdova-Alarcon E, et al.: TP53 polymorphisms allow for

genetic sub-grouping of the canine transmisible venereal tumor, J Vet Sci 10(4):353–355, 2009.

225. Stockman D, Ferrari HF, Andrade AL, et al.: Detection of the tumour suppressor gene TP53
and expression of p53, Bcl-2 and p63 proteins in canine transmissible venereal tumour, Vet Comp
Oncol 9(4):251–259, 2011.

226. Fenton MA, Yang TJ: Role of humoral immunity in progressive and regressive and metastatic
growth of the canine transmisible venereal sarcoma, Oncology 45:210–213, 1988.

227. Perez J, Day MJ, Mozos E: Immunohistochemical study of the local inflammatory infiltrate in
spontaneous canine transmisible venereal tumour at different stages of growth, Vet Immunol
Immunopathol 64:133–147, 1998.

228. Hsiao YW, Liao KW, Hung SW, et al.: Effect of tumor infiltrating lymphocytes on the expression
of MHC molecules in canine transmissible venereal tumor cells, Vet Immunol Immunopathol 87:19–
27, 2002.

229. Liao KW, Hung SW, Hsiao YW, et al.: Canine transmissible venereal tumor cell depletion of B
lymphocytes: molecule(s) specifically toxic for B cells, Vet Immunol Immunopathol 92:149–162,
2003.

230. Hsiao YW, Liao KW, Hung SW, et al.: Tumor-infiltrating lymphocyte secretion of IL-6
antagonizes tumor-derived TGF-βl and restores the lymphokine-activated killing activity, J Immunol
172:1508–1514, 2004.

231. Siddle HV, Kaufman J: Immunology of naturally transmisible tumours, Immunology 144(1):11–
20, 2015.

232. Gonzalez CM, Griffey SM, Naydan DK, et al.: Canine transmisible venereal tumour: a
morphological and immunohistochemical study of 11 tumours in growth phase and during
regression after chemotherapy, J Comp Path 122:241–248, 2000.
233. Mukaratirwa S, Chimonyo M, Obwolo M, et al.: Stromal cells and extracellular matrix
components in spontaneous canine transmisible venereal tumour at different stages of growth,
Histol Histopathol 9:1117–1123, 2004.

234. Liu CC, Wang YS, Lin CY, et al.: Transient downregulation of monocyte-derived dendritic-cell
differentiation, function, and survival during tumoral progression and regression in an in vivo canine
model of transmissible venereal tumor, Cancer Immunol Immunother 57:479–491, 2008.

235. Fassati A, Mitchison NA: Testing the theory of immune selection in cancers that break the
rules of transplantation, Cancer Immunol Immunother 59:643–651, 2010.

236. Hsiao YW, Liao KW, Chung TF, et al.: Interactions of host IL-6 and IFN-γ and cancer-derived
TGF-ß1 on MHC molecule expression during tumor spontaneous regression, Cancer Immunol
Immunother 57:1091–1104, 2008.

237. Ballestero Feo H, Montoya Flórez L, Yamatogi RS, et al.: Does the tumour microenvironment
alter tumorigenesis and clinical response in transmissible venereal tumour in dogs? Vet Comp
Oncol 16:370–378, 2018.

238. Chiang HC, Liao AT, Jan TR, et al.: Gene-expression profiling to identify genes related to
spontaneous tumor regression in a canine cancer model, Vet Immunol Immunopathol 151:207–216,
2013.

239. Frampton D, Schwenzer H, Marino G, et al.: Molecular signatures of regression of the canine
transmissible venereal tumor, Cancer Cell 33:620–633, 2018.

240. Cohen D: Detection of humoral antibody to the transmisible venereal tumour of the dog, Int J
Cancer 10:207–212, 1972.

241. Calvert CA, Leifer CE, MacEwen EG: Vincristine for treatment of transmissible venereal tumor
in the dog, J Am Vet Med Assoc 181:163–164, 1982.

242. Yang TJ, Palker TJ, Harding MW: Tumor size, leukocyte adherence inhibition and serum level
of tumor antigen in dogs with the canine transmissible venereal sarcoma, Cancer Immunol
Immunother 33:255–262, 1991.

243. Batamuzi EK, Kristensen F: Urinary tract infection: the role of canine transmissible venereal
tumour, J Small Anim Pract 37:276– 279, 1996.

244. Amber EI, Henderson RA, Adeyanju JB, et al.: Single-drug chemotherapy of canine
transmissible venereal tumor with cyclophosphamide, methotrexate, or vincristine, J Vet Intern Med
4:144–147, 1990.

245. Singh J, Rana JS, Sood N, et al.: Clinico-pathological studies on the effect of different anti-
neoplastic chemotherapy regimens on transmissible venereal tumours in dogs, Vet Res Comm
20:71–81, 1996.

246. Nak D, Nak Y, Cangul IT, et al.: A clinico-pathological study on the effect of vincristine on
transmissible venereal tumour in dogs, J Vet Med A 52:366–370, 2005.

247. Scarpelli KC, Valladao ML, Metze K: Predictive factors for the regression of canine
transmissible venereal tumor during vincristine therapy, Vet J 183:362–363, 2010.

248. Fathi M, Ashry M, Ali KM, et al.: Clinico-pathological evaluation and treatment outcomes of
canine transmissible venereal tumor using three different protocols, Pak Vet J 38(2):204–208, 2018.

249. Thrall DE: Orthovoltage radiotherapy of canine transmissible venereal tumors, Vet Radiol
23:217–219, 1982.
250. Idowu AL: A retrospective evaluation of four surgical methods of treating canine transmissible
venereal tumour, J Small Anim Pract 25:193–198, 1984.

251. Amber EI, Henderson RA: Canine transmissible venereal tumor evaluation of surgical excision
of primary and metastatic lesions in Zaria-Nigeria, J Am Anim Hosp Assoc 18:350–352, 1982.

252. Knapp DW, Richardson RC, Bottoms GD, et al.: Phase I trial of piroxicam in 62 dogs bearing
naturally occurring tumors, Chemother Pharmacol 29:214–218, 1992.

253. Ahmed M, Liu Z, Afzal KS, et al.: Radiofrequency ablation: effect of surrounding tissue
composition on coagulation necrosis in a canine tumor model, Radiology 230:761–767, 2004.

254. Suzuki DOH, Berkenbrock JA, de Olveira KD, et al.: Novel application for
electrochemotherapy: immersion of nasal cavity in dog, Artif Organs 41(8):767–784, 2017.

255. Chou PC, Chuang TF, Jan TR, et al.: Effects of immunotherapy of IL-6 and IL-15 plasmids on
transmissible venereal tumor in beagles, Vet Immunol Immunopathol 130:25–34, 2009.

256. Pai CC, Kuo TF, Mao SJT, et al.: Immunopathogenic behaviors of canine transmissible
venereal tumor in dogs following an immunotherapy using dendritic/tumor cell hybrid, Vet Immunol
Immunopathol 139:187–199, 2011.

257. Den Otter W, Hack M, Jacobs JJ, et al.: Effective treatment of transmissible venereal tumors in
dogs with vincristine and IL2, Anticancer Res 35(6):3385–3391, 2015.

258. Geib LW, DeNarvaez F, Eby CH: Pleural mesothelioma in a dog, J Am Vet Med Assoc
140:1317–1319, 1962.

259. Cihak RW, Roen DR, Klaassen J: Malignant mesothelioma of the tunica vaginalis in a dog, J
Comp Pathol 96:459–462, 1986.

260. Vascellari M, Carminato A, Camali G, et al.: Malignant mesothelioma of the tunica vaginalis
testis in a dog: Histological and immunohistochemical characterization, J Vet Diagn Invest 23:135–
139, 2011.

261. Dubielzig RR: Sclerosing mesothelioma in five dogs, J Am Anim Hosp Assoc 15:745–748,
1979.

262. Thrall DE, Goldschmidt MH: Mesothelioma in the dog: six case reports, J Am Vet Radiol Soc
19:107–115, 1978.

263. Morini M, Bettini G, Morandi F, et al.: Deciduoid peritoneal mesothelioma in a dog, Vet Pathol
43:198–201, 2006.

264. Son NV, Chambers JK, Shiga T, et al.: Sarcomatoid mesothelioma of tunica vaginalis testis in
the right scrotum of a dog, J Vet Med Sci, 2018. https://doi.org/10.1292/jvms.18-0186. epub ahead
of print.

265. Kobayashi Y, Usuda H, Ochiai K, et al.: Malignant mesothelioma with metastases and mast
cell leukaemia in a cat, J Comp Path 111:453–458, 1994.

266. Tilley LP, Owens JM, Wilkins RJ, et al.: Pericardial mesothelioma with effusion in a cat, J Am
Anim Hosp Assoc 60– 65, 1975.

267. Umphlet RC, Bertoy RW: Abdominal mesothelioma in a cat, Mod Vet Pract 69:71–73, 1988.

268. Bacci B, Morandi F, De Meo M, et al.: Ten cases of feline mesothelioma: an

immunohistochemical and ultrastructural study, J Comp Pathol 134:347–354, 2006.
269. Heerkens TM, Smith JD, Fox L, et al.: Peritoneal fibrosarcomatous mesothelioma in a cat, J
Vet Diagn Invest 23:593–597, 2011.

270. Schaer M, Meyer D: Benign peritoneal mesothelioma, hyperthyroidism, nonsuppurative

hepatitis, and chronic disseminated intravascular coagulation in a cat: a case report, J Am Anim
Hosp Assoc 24:195–202, 1988.

271. Glickman LT, Domanski LM, Maguire TG, et al.: Mesothelioma in pet dogs associated with
exposure of their owners to asbestos, Environ Res 32:305–313, 1983.

272. Harbison ML, Godleski JJ: Malignant mesothelioma in urban dogs, Vet Pathol 20:531–540,
1983.

273. Hughes RS: Malignant pleural mesothelioma, Am J Med Sci 329:29–44, 2005.

274. Yap TA, Aerts JG, Popat S, et al.: Novel insights into mesothelioma biology and implications
for therapy, Nat Rev Cancer 17:475–488, 2017.

275. Bueno R, Stawiski EW, Goldstein LD, et al.: Comprehensive genomic analysis of malignant
pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations, Nat
Genet 48:407–416, 2016.

276. Ugurluer G, Chang K, Gamez ME, et al.: Genome-based mutational analysis by next
generation sequencing in patients with malignant pleural and peritoneal mesothelioma, Anticancer
Res 36:2331–2338, 2016.

277. Belli C, Anand S, Tassi G, et al.: Translational therapies for malignant pleural mesothelioma,
Expert Rev Respir Med 4:249–260, 2010.

278. Machida N, Tanaka R, Takemura N, et al.: Development of pericardial mesothelioma in golden

retrievers with a long-term history of idiopathic haemorrhagic pericardial effusion, J Comp Pathol
131:166–175, 2004.

279. Kim JH, Choi YK, Yoon HY, et al.: Juvenile malignant mesothelioma in a dog, J Vet Med Sci
64:269–271, 2002.

280. Vural SA, Ozyildiz Z, Ozsoy SY: Pleural mesothelioma in a ninemonth- old dog, Ir Vet J 60:30–
33, 2007.

281. Leisewitz AL, Nesbit JW: Malignant mesothelioma in a sevenweek- old puppy, J S Afr Vet
Assoc 63:70–73, 1992.

282. Corson JM: Pathology of mesothelioma, Thorac Surg Clin 14:447–460, 2004.

283. Geninet C, Bernex F, Rakotovao F, et al.: Sclerosing peritoneal mesothelioma in a dog - a

case report, J Vet Med A Physiol Pathol Clin Med 50:402–405, 2003.

284. Schoning P, Layton CE, Fortney WD, et al.: Sclerosing peritoneal mesothelioma in a dog
evaluated by electron microscopy and immunoperoxidase techniques, J Vet Diagn Invest 4:217–
220, 1992.

285. D’Angelo AR, Di Francesco G: Sclerosing peritoneal mesothelioma in a dog: Histopathological,

histochemical and immunohistochemical investigations, Vet Ital 50:301–305, 2014.

286. Dias Pereira P, Azevedo M, Gartner F: Case of malignant biphasic mesothelioma in a dog, Vet
Rec 149:680–681, 2001.
287. Sato T, Miyoshi T, Shibuya H, et al.: Peritoneal biphasic mesothelioma in a dog, J Vet Med A
Physiol Pathol Clin Med 52:22–25, 2005.

288. Al-Dissi AN, Philibert H: A case of biphasic mesothelioma with osseous and chondromatous
differentiation in a cat, Can Vet J 52:534–536, 2011.

289. DiPinto MN, Dunstan RW, Lee C: Cystic, peritoneal mesothelioma in a dog, J Am Anim Hosp
Assoc 31:385–389, 1995.

290. Cobb MA, Brownlie SE: Intrapericardial neoplasia in 14 dogs, J Small Anim Pract 33:309–316,
1992.

291. McDonough SP, MacLachlan NJ, Tobias AH: Canine pericardial mesothelioma, Vet Pathol
29:256–260, 1992.

292. MacDonald KA, Cagney O, Magne ML: Echocardiographic and clinicopathologic

characterization of pericardial effusion in dogs: 107 cases (1985-2006), J Am Vet Med Assoc
235:1456–1461, 2009.

293. Gumber S, Fowlkes N, Cho DY: Disseminated sclerosing peritoneal mesothelioma in a dog, J
Vet Diagn Invest 23:1046–1050, 2011.

294. Stepien RL, Whitley NT, Dubielzig RR: Idiopathic or mesothelioma-related pericardial effusion:
clinical findings and survival in 17 dogs studied retrospectively, J Small Anim Pract 41:342–347,
2000.

295. Echandi RL, Morandi F, Newman SJ, et al.: Imaging diagnosiscanine thoracic mesothelioma,
Vet Radiol Ultrasound 48:243–245, 2007.

296. Reetz JA, Buza EL, Krick EL: Ct features of pleural masses and nodules, Vet Radiol
Ultrasound 53:121–127, 2012.

297. Watton TC, Lara-Garcia A, Lamb CR: Can malignant and inflammatory pleural effusions in
dogs be distinguished using computed tomography? Vet Radiol Ultrasound 58:535–541, 2017.

298. Fine DM, Tobias AH, Jacob KA: Use of pericardial fluid ph to distinguish between idiopathic
and neoplastic effusions, J Vet Intern Med 17:525–529, 2003.

299. de Laforcade AM, Freeman LM, Rozanski EA, et al.: Biochemical analysis of pericardial fluid
and whole blood in dogs with pericardial effusion, J Vet Intern Med 19:833–836, 2005.

300. Hirschberger J, Pusch S: Fibronectin concentrations in pleural and abdominal effusions in

dogs and cats, J Vet Intern Med 10:321–325, 1996.

301. Reggeti F, Brisson B, Ruotsalo K, et al.: Invasive epithelial mesothelioma in a dog, Vet Pathol
42:77–81, 2005.

302. Peters M, Tenhundfeld J, Stephan I, et al.: Embolized mesothelial cells within mediastinal
lymph nodes of three dogs with idiopathic haemorrhagic pericardial effusion, J Comp Pathol
128:107–112, 2003.

303. Ali G, Bruno R, Fontanini G: The pathological and molecular diagnosis of malignant pleural
mesothelioma: a literature review, J Thorac Dis 10:S276–S284, 2018.

304. Liptak JM, Brebner NS: Hemidiaphragmatic reconstruction with a transversus abdominis
muscle flap after resection of a solitary diaphragmatic mesothelioma in a dog, J Am Vet Med Assoc
228:1204– 1208, 2006.
305. Kerstetter KK, Krahwinkel DJ, Millis DL, et al.: Pericardiectomy in dogs: 22 cases (1978-1994),
J Am Vet Med Assoc 211:736–740, 1997.

306. Dunning D, Monnet E, Orton EC, et al.: Analysis of prognostic indicators for dogs with
pericardial effusion: 46 cases (1985-1996), J Am Vet Med Assoc 212:1276–1280, 1998.

307. Closa JM, Font A, Mascort J: Pericardial mesothelioma in a dog: long-term survival after
pericardiectomy in combination with chemotherapy, J Small Anim Pract 40:383–386, 1999.

308. Jackson J, Richter K, Launer D: Thoracoscopic partial pericardiectomy in 13 dogs, J Vet Intern
Med 13:529–533, 1999.

309. Brisson BA, Reggeti F, Bienzle D: Portal site metastasis of invasive mesothelioma after
diagnostic thoracoscopy in a dog, J Am Vet Med Assoc 229:980–983, 2006.

310. Atencia S, Doyle RS, Whitley NT: Thoracoscopic pericardial window for management of
pericardial effusion in 15 dogs, J Small Anim Pract 54:564–569, 2013.

311. Case JB, Maxwell M, Aman A, et al.: Outcome evaluation of a thoracoscopic pericardial
window procedure or subtotal pericardectomy via thoracotomy for the treatment of pericardial
effusion in dogs, J Am Vet Med Assoc 242:493–498, 2013.

312. Brooks AC, Hardie RJ: Use of the PleuralPort device for management of pleural effusion in six
dogs and four cats, Vet Surg 40:935–941, 2011.

313. Moore AS, Kirk C, Cardona A: Intracavitary cisplatin chemotherapy experience with six dogs, J
Vet Intern Med 5:227–231, 1991.

314. Sparkes A, Murphy S, McConnell F, et al.: Palliative intracavitary carboplatin therapy in a cat
with suspected pleural mesothelioma, J Feline Med Surg 7:313–316, 2005.

315. Spugnini EP, Crispi S, Scarabello A, et al.: Piroxicam and intracavitary platinum-based
chemotherapy for the treatment of advanced mesothelioma in pets: preliminary observations, J Exp
Clin Cancer Res 27(6), 2008.

316. Seo KW, Choi US, Jung YC, et al.: Palliative intravenous cisplatin treatment for concurrent
peritoneal and pleural mesothelioma in a dog, J Vet Med Sci 69:201–204, 2007.

317. Campbell NP, Kindler HL: Update on malignant pleural mesothelioma, Semin Respir Crit Care
Med 32:102–110, 2011.

318. Noonan CW: Environmental asbestos exposure and risk of mesothelioma, Ann Transl Med
5:234, 2017.

319. Wang S, Ma K, Wang Q, et al.: The revised staging system for malignant pleural mesothelioma
based on surveillance, epidemiology, and end results database, Int J Surg 48:92–98, 2017.

320. Pass HI, Goparaju C, Espin-Garcia O, et al.: Plasma biomarker enrichment of clinical
prognostic indices in malignant pleural mesothelioma, J Thorac Oncol 11:900–909, 2016.

321. Katzman D, Sterman DH: Updates in the diagnosis and treatment of malignant pleural
mesothelioma, Curr Opin Pulm Med, 2018. https://doi.org/10.1097/MCP.0000000000000489. epub
ahead of print.

322. Kapeles M, Gensheimer MF, Mart DA, et al.: Trimodality treatment of malignant pleural
mesothelioma: an institutional review, Am J Clin Oncol 41:30–35, 2018.
323. Ware WA, Hopper DL: Cardiac tumors in dogs: 1982–1995, J Vet Intern Med 13:95–103,
1999.

324. Walter JH, Rudolph R: Systemic, metastatic, eu- and heterotope tumours of the heart in
necropsied dogs, Zentralbl Veterinarmed A 43:31–45, 1996.

325. Girard C, Hélie P, Odin M: Intrapericardial neoplasia in dogs, J Vet Diagn Invest 11:73–78,
1999.

326. Aupperle H, März I, Ellenberger C, et al.: Primary and secondary heart tumours in dogs and
cats, J Comp Pathol 136:18–26, 2007.

327. Treggiari E, Pedro B, Dukes-McEwan J, et al.: A descriptive review of cardiac tumours in dogs
and cats, Vet Comp Oncol 15:273–288, 2017.

328. Massimo V, Rossella T, Federica R, et al.: Whole body computed tomographic characteristics
of skeletal and cardiac muscular metastatic neoplasia in dogs and cats, Vet Radiol Ultrasound
54:223– 230, 2013.

329. Janus I, Nowak M, Noszczyk-Nowak A, et al.: Epidemiological and pathological features of

primary cardiac tumours in dogs from Poland in 1970-2014, Acta Vet Hung 64:90–102, 2016.

330. Aronsohn M: Cardiac hemangiosarcoma in the dog: a review of 38 cases, J Am Vet Med
Assoc 187:922–926, 1985.

331. Yamamoto S, Hoshi K, Hirakawa A, et al.: Epidemiological, clinical and pathological features of
primary cardiac hemangiosarcoma in dogs: a review of 51 cases, J Vet Med Sci 75:1433–1441,
2013.

332. Weisse C, Soares N, Beal MW, et al.: Survival times in dogs with right atrial hemangiosarcoma
treated by means of surgical resection with or without adjuvant chemotherapy: 23 cases (1986–
2000), J Am Vet Med Assoc 226:575–579, 2005.

333. Hayes HM: An hypothesis for the aetiology of canine chemoreceptor system neoplasms,
based upon an epidemiological study of 73 cases among hospital patients, J Small Anim Pract
16:337–343, 1975.

334. Patnaik AK, Liu S-K, Hurvitz AI, et al.: Canine chemodectoma (extra-adrenal paragangliomas)-
a comparative study, J Small Anim Pract 16:785–801, 1975.

335. Noszczyk-Nowak A, Nowak M, Paslawska U, et al.: Cases with manifestation of

chemodectoma diagnosed in dogs in Department of Internal Diseases with Horses, Dogs and Cats
Clinic, Veterinary Medicine Faculty, University of Environmental and Life Sciences, Wroclaw,
Poland, Acta Vet Scand 52, 2010.

336. Vicari ED, Brown DC, Holt DE, et al.: Survival times of and prognostic indicators for dogs with
heart base masses: 25 cases (1986–1999), J Am Vet Med Assoc 219:485–487, 2001.

337. Ehrhart N, Ehrhart EJ, Willis J, et al.: Analysis of factors affecting survival in dogs with aortic
body tumors, Vet Surg 31:44–48, 2002.

338. Ware WA: Cardiac neoplasia. In Kirk RW, Bonagura JD, editors: Kirk’s current veterinary
therapy XII, Philadelphia, 1995, WB Saunders, pp 873–876.

339. Amati M, Venco L, Roccabianca P, et al.: Pericardial lymphoma in seven cats, J Feline Med
Surg 16:507–512, 2014.
340. Carter TD, Pariaut R, Snook E, et al.: Multicentric lymphoma mimicking decompensated
hypertrophic cardiomyopathy in a cat, J Vet Intern Med 22:1345–1347, 2008.

341. Hansen Sonya C, Smith Annette N, Kuo Kendon W, et al.: Metastatic neuroendocrine
carcinoma of aortic body origin in a cat, Vet Clin Pathol 45:490–494, 2016.

342. Willis R, Williams AE, Schwarz T, et al.: Aortic body chemodectoma causing pulmonary
oedema in a cat, J Small Anim Pract 42:20–23, 2008.

343. Paltrinieri S, Riccaboni P, Rondena M, et al.: Pathologic and immunohistochemical findings in

a feline aortic body tumor, Vet Pathol 41:195–198, 2004.

344. Tilley LP, Bond B, Patnaik AK, et al.: Cardiovascular tumors in the cat, J Am Anim Hosp Assoc
17:1009–1021, 1981.

345. Merlo M, Bo S, Ratto A: Primary right atrium haemangiosarcoma in a cat, J Feline Med Surg
4:61–64, 2002.

346. George C, Steinberg H: An aortic body carcinoma with multifocal thoracic metastases in a cat,
J Comp Pathol 101:467–469, 1989.

347. Berg J: Pericardial disease and cardiac neoplasia, Semin Vet Med Surg (Small Anim) 9:185–
191, 1994.

348. MacGregor JM, Faria MLE, Moore AS, et al.: Cardiac lymphoma and pericardial effusion in
dogs: 12 cases (1994–2004), J Am Vet Med Assoc 227:1449–1453, 2005.

349. Stern JA, Tobias JR, Keene BW: Complete atrioventricular block secondary to cardiac
lymphoma in a dog, J Vet Cardiol 14:537–539, 2012.

350. Sims CS, Tobias AH, Hayden DW, et al.: Pericardial effusion due to primary cardiac
lymphosarcoma in a dog, J Vet Intern Med 17:923–927, 2003.

351. Bracha S, Caron I, Holmberg DL, et al.: Ectopic thyroid carcinoma causing right ventricular
outflow tract obstruction in a dog, J Am Anim Hosp Assoc 45:138–141, 2009.

352. Boes K, Messick J, Green H, et al.: What is your diagnosis? Impression smear from an
intracardiac mass in a dog, Vet Clin Pathol 39:119–120, 2010.

353. Kang M-H, Kim D-Y, Park H-M: Ectopic thyroid carcinoma infiltrating the right atrium of the
heart in a dog, Can Vet J 53:177– 181, 2012.

354. Rioja E, Beaulieu K, Holmberg DL: Anesthetic management of an off-pump open-heart surgery
in a dog, Vet Anaesth Analg 36:361–368, 2009.

355. Ridge L, Swinney G: Angiotrophic intravascular lymphosarcoma presenting as bi‐cavity

effusion in a dog, Aust Vet J 82:616–618, 2004.

356. Karlin ET, Yang VK, Prabhakar M, et al.: Extracardiac intrapericardial myxosarcoma causing
right ventricular outflow tract obstruction in a dog, J Vet Cardiol 20:129–135, 2018.

357. Yamamoto S, Fukushima R, Kobayashi M, et al.: Mixed form of pericardial mesothelioma with
osseous differentiation in a dog, J Comp Pathol 149:229–232, 2013.

358. Southerland EM, Miller RT, Jones CL: Primary right atrial chondrosarcoma in a dog, J Am Vet
Med Assoc 203:1697–1698, 1993.

359. Bright JM, Toal RL, Blackford LM: Right ventricular outflow obstruction caused by primary
cardiac neoplasia, J Vet Intern Med 4:12–16, 1990.
360. Brower A, Herold LV, Kirby BM: Canine cardiac mesothelioma with granular cell morphology,
Vet Pathol 43:384–387, 2006.

361. Adissu HA, Hayes G, Wood GA, et al.: Cardiac myxosarcoma with adrenal adenoma and
pituitary hyperplasia resembling carney complex in a dog, Vet Pathol 47:354–357, 2010.

362. Beal MW, McGuire LD, Langohr IM: Axillary artery tumor embolism secondary to mitral valve
myxosarcoma in a dog, J Vet Emerg Crit Care 24:751–758, 2014.

363. Hsieh BM, Cohen M, Levitzke B, et al.: What is your diagnosis? Low-grade myxosarcoma
arising from the heart valve, J Am Vet Med Assoc 242:1067–1068, 2013.

364. Briggs OM, Kirberger RM, Goldberg NB: Right atrial myxosarcoma in a dog, J S Afr Vet Assoc
68:144–146, 1997.

365. Foale RD, White RAS, Harley R, et al.: Left ventricular myxosarcoma in a dog, J Small Anim
Pract 44:503–507, 2006.

366. Worley DR, Orton EC, Kroner KT: Inflow venous occlusion for intracardiac resection of an
occluding right ventricular tumor, J Am Anim Hosp Assoc 52:259–264, 2016.

367. Dupuy-Mateos A, Wotton PR, Blunden AS, et al.: Primary cardiac chondrosarcoma in a paced
dog, Vet Rec 163:272, 2008.

368. Caro-Vadillo A, Pizarro-Díaz M, Martínez-Merlo E, et al.: Clinical and pathological features of a

cardiac chondrosarcoma in a dog, Vet Rec 155:678, 2004.

369. Asakawa MG, Ames MK, Kim Y: Primary cardiac spindle cell tumor in a dog, Can Vet J
54:672–674, 2013.

370. Speltz MC, Manivel JC, Tobias AH, et al.: Primary cardiac fibrosarcoma with pulmonary
metastasis in a Labrador retriever, Vet Pathol 44:403–407, 2007.

371. Madarame H, Sato K, Ogihara K, et al.: Primary cardiac fibrosarcoma in a dog, J Vet Med Sci
66:979–982, 2004.

372. Wohlsein P, Cichowski S, Baumgärtner W: Primary endocardial malignant spindle-cell

sarcoma in the right atrium of a dog resembling a malignant peripheral nerve sheath tumour, J
Comp Pathol 132:340–345, 2005.

373. Fries R, Achen S, O’Brien MT, et al.: Primary cardiac tumor presenting as left ventricular
outflow tract obstruction and complex arrhythmia, J Vet Cardiol 19:441–447, 2017.

374. Gómez-Laguna J, Barranco I, Rodríguez-Gómez IM, et al.: Malignant mesenchymoma of the

heart base in a dog with infiltration of the pericardium and metastasis to the lung, J Comp Pathol
147:195–198, 2012.

375. Machida N, Kobayashi M, Tanaka R, et al.: Primary malignant mixed mesenchymal tumour of
the heart in a dog, J Comp Pathol 128:71–74, 2003.

376. Timian J, Yoshimoto SK, Bruyette DS: Extraskeletal osteosarcoma of the heart presenting as
infective endocarditis, J Am Anim Hosp Assoc 47:129–132, 2011.

377. Sato T, Shibuya H, Suzuki K, et al.: Extraskeletal osteosarcoma in the pericardium of a dog,
Vet Rec 155:780, 2004.

378. LaRock RG, Ginn PE, Burrows CF, et al.: Primary mesenchymal chondrosarcoma in the
pericardium of a dog, J Vet Diagn Invest 9:410–413, 1997.
379. Perez J, Perez-Rivero A, Montoya A, et al.: Right-sided heart failure in a dog with primary
cardiac rhabdomyosarcoma, J Am Anim Hosp Assoc 34:208–211, 1998.

380. Sanford SE, Hoover DM, Miller RB: Primary cardiac granular cell tumor in a dog, Vet Pathol
21:489–494, 1984.

381. Krotje LJ, Ware WA, Niyo Y: Intracardiac rhabdomyosarcoma in a dog, J Am Vet Med Assoc
197:368–371, 1990.

382. Vicini DS, Didier PJ, Ogilvie GK: Cardiac fibrosarcoma in a dog, J Am Vet Med Assoc
189:1486–1488, 1986.

383. Almes KM, Heaney AM, Andrews GA: Intracardiac ectopic thyroid carcinosarcoma in a dog,
Vet Pathol 45:500–504, 2008.

384. Fews D, Scase TJ, Battersby IA: Leiomyosarcoma of the pericardium, with epicardial
metastases and peripheral eosinophilia in a dog, J Comp Pathol 138:224–228, 2008.

385. Cobb MA, Brownlie SE: Intrapericardial neoplasia in 14 dogs, J Small Anim Pract 33:309–316,
1992.

386. de Nijs MI, Vink A, Bergmann W, et al.: Left ventricular cardiac myxoma and sudden death in a
dog, Acta Vet Scand 58:41, 2016.

387. Fernandez-del Palacio MJ, Sanchez J, Talavera J, et al.: Left ventricular inflow tract
obstruction secondary to a myxoma in a dog, J Am Anim Hosp Assoc 47:217–223, 2011.

388. Akkoc A, Ozyigit MO, Cangul IT: Valvular cardiac myxoma in a dog, J Vet Med A Physiol
Pathol Clin Med 54:356–358, 2007.

389. Machida N, Hoshi K, Kobayashi M, et al.: Cardiac myxoma of the tricuspid valve in a dog, J
Comp Pathol 129:320–324, 2003.

390. Brambilla Paola G, Roccabianca P, Locatelli C, et al.: Primary cardiac lipoma in a dog, J Vet
Intern Med 20:691–693, 2008.

391. Ben‐Amotz R, Ellison GW, Thompson MS, et al.: Pericardial lipoma in a geriatric dog with an
incidentally discovered thoracic mass, J Small Anim Pract 48:596–599, 2007.

392. Kolm US, Kleiter M, Kosztolich A, et al.: Benign intrapericardial lipoma in a dog, J Vet Cardiol
4:25–29, 2002.

393. Simpson DJ, Hunt GB, Church DB, et al.: Benign masses in the pericardium of two dogs, Aust
Vet J 77:225–229, 1999.

394. Di Palma S, Lombard C, Kappeler A, et al.: Intracardiac ectopic thyroid adenoma in a dog, Vet
Rec 167:709, 2010.

395. Machida N, Katsuda S, Yamamura H, et al.: Myocardial hamartoma of the right atrium in a
dog, J Comp Pathol 127:297–300, 2002.

396. Tjostheim SS, Kellihan HB, Csomos RA, et al.: Vascular hamartoma in the right ventricle of a
dog: Diagnosis and treatment, J Vet Cardiol 17:321–328, 2015.

397. Thomason JD, Rapoport G, Fallaw T, et al.: Pulmonary edema secondary to a cardiac
schwannoma in a dog, J Vet Cardiol 17:149– 153, 2015.

398. Gallay J, Bélanger MC, Hélie P, et al.: Cardiac leiomyoma associated with advanced
atrioventricular block in a young dog, J Vet Cardiol 3:71–77, 2011.
399. Lombard CW, Goldschmidt MH: Primary fibroma in the right atrium of a dog, J Small Anim
Pract 21:439–448, 1980.

400. Hilbe M, Hauser B, Zlinszky K, et al.: Haemangiosarcoma with a metastasis of a malignant

mixed mammary gland tumour in a dog, J Vet Med A Physiol Pathol Clin Med 49:443–444, 2002

401. Ogilvie GK, Brunkow CS, Daniel GB, et al.: Malignant lymphoma with cardiac and bone
involvement in a dog, J Am Vet Med Assoc 194:793–796, 1989.

402. Lowe AD: Alimentary lymphosarcoma in a 4-year-old Labrador retriever, Can Vet J 45:610–
612, 2004.

403. Wilkerson MJ, Dolce K, DeBey BM, et al.: Metastatic balloon cell melanoma in a dog, Vet Clin
Pathol 32:31–36, 2003.

404. Sabocanec R, Culjak K, Vrbanac L, et al.: A case of metastasizing ovarian granulosa cell
tumour in the myocardium of a bitch, Acta Vet Hung 44:189–194, 1996.

405. Uno Y, Momoi Y, Watari T, et al.: Malignant histiocytosis with multiple skin lesions in a dog, J
Vet Med Sci 55:1059–1061, 1993.

406. Sako T, Kitamura N, Kagawa Y, et al.: Immunohistochemical evaluation of a malignant

pheochromocytoma in a wolfdog, Vet Pathol 38:447–450, 2001.

407. Guglielmini C, Civitella C, Malatesta D, et al.: Metastatic pericardial tumors in a dog with
equivocal pericardial cytological findings, J Am Anim Hosp Assoc 43:284–287, 2007.

408. Weishaar KM, Edmondson EF, Thamm DH, et al.: Malignant mesenchymoma with widespread
metastasis including bone marrow involvement in a dog, Vet Clin Pathol 43:447–452, 2014.

409. Akkoc A, Ozyigit MO, Yilmaz R, et al.: Cardiac metastasising rhabdomyosarcoma in a great
Dane, Vet Rec 158:803, 2006.

410. Ramoo S: Hypertrophic osteopathy associated with two pulmonary tumours and myocardial
metastases in a dog: a case report, N Z Vet J 61:45–48, 2013.

411. Wang FI, Liang SL, Eng HL, et al.: Disseminated liposarcoma in a dog, J Vet Diagn Invest
17:291–294, 2005.

412. Shih JL, Brenn S, Schrope DP: Cardiac involvement secondary to mediastinal lymphoma in a
cat: regression with chemotherapy, J Vet Cardiol 16:115–120, 2014.

413. Less R, Bright J, Orton E: Intrapericardial cyst causing cardiac tamponade in a cat, J Am Anim
Hosp Assoc 36:115–119, 2000.

414. Sarah MS, Janice MB: Chronic cardiac tamponade in a cat caused by an intrapericardial biliary
cyst, J Feline Med Surg 12:338–340, 2010.

415. Kobayashi R, Ohsaki Y, Yasuno K, et al.: A malignant and metastasizing feline cardiac
ganglioneuroma, J Vet Diagn Invest 24:412–417, 2012.

416. Venco L, Kramer L, Sola LB, et al.: Primary cardiac rhabdomyosarcoma in a cat, J Am Anim
Hosp Assoc 37:159–163, 2001.

417. Campbell MD, Gelberg HB: Endocardial ossifying myxoma of the right atrium in a cat, Vet
Pathol 37:460–462, 2000.

418. Klausner JS, Bell FW, Hayden DW, et al.: Hypercalcemia in two cats with squamous cell
carcinomas, J Am Vet Med Assoc 196:103– 105, 1990.
419. Shaw TE, Harkin KR, Nietfeld J, et al.: Aortic body tumor in fullsibling English bulldogs, J Am
Anim Hosp Assoc 46:366–370, 2010.

420. Rancilio NJ, Higuchi T, Gagnon J, et al.: Use of three-dimensional conformal radiation therapy
for treatment of a heart base chemodectoma in a dog, J Am Vet Med Assoc 241:472–476, 2012.

421. Cote E, MacDonald KA, Meurs KM, et al.: Cardiac neoplasia. In Cote E, MacDonald KA, Meurs
KM, et al., editors: Feline cardiology, ed 1, West Sussex, UK, 2011, John Wiley & Sons, pp 201–
204.

422. Pedro B, Linney C, Navarro-Cubas X, et al.: Cytological diagnosis of cardiac masses with
ultrasound guided fine needle aspirates, J Vet Cardiol 18:47–56, 2016.

423. Nelson OL, Ware WA: Pericardial effusion. In Bonagura JD, Twedt DC, editors: Kirk’s current
veterinary therapy XV, Philadelphia, 2014, WB Saunders, pp 816–823.

424. Im M, Stern JA: ECG of the month, J Am Vet Med Assoc 248:497–500, 2016.

425. Holt D, Van Winkle T, Schelling C, et al.: Correlation between thoracic radiographs and
postmortem findings in dogs with hemangiosarcoma: 77 cases (1984-1989), J Am Vet Med Assoc
200:1535–1539, 1992.

426. Gidlewski J, Petrie JP: Pericardiocentesis and principles of echocardiographic imaging in the
patient with cardiac neoplasia, Clin Tech Small Anim Pract 18:131–134, 2003.

427. Thomas WP, Sisson D, Bauer TG, et al.: Detection of cardiac masses in dogs by two-
dimensional echocardiography, Vet Radiol 25:65–72, 1984.

428. Fruchter AM, Miller CW, O’Grady MR: Echocardiographic results and clinical considerations in
dogs with right atrial/auricular masses, Can Vet J 33:171–174, 1992.

429. MacDonald KA, Cagney O, Magne ML: Echocardiographic and clinicopathologic

characterization of pericardial effusion in dogs: 107 cases (1985-2006), J Am Vet Med Assoc
235:1456–1461, 2009.

430. Rajagopalan V, Jesty SA, Craig LE, et al.: Comparison of presumptive echocardiographic and
definitive diagnoses of cardiac tumors in dogs, J Vet Intern Med 27:1092–1096, 2013.

431. Rush JE, Keene BW, Fox PR: Pericardial disease in the cat: a retrospective evaluation of 66
cases, J Am Anim Hosp Assoc 26:39–46, 1990.

432. De Rycke LM, Gielen IM, Simoens PJ, et al.: Computed tomography and cross-sectional
anatomy of the thorax in clinically normal dogs, Am J Vet Res 66:512–524, 2005.

433. Mai W, Weisse C, Sleeper Meg M: Cardiac magnetic resonance imaging in normal dogs and
two dogs with heart base tumor, Vet Radiol Ultrasound 51:428–435, 2010.

434. Hansen AE, McEvoy F, Engelholm SA, et al.: FDG PET/CT imaging in canine cancer patients,
Vet Radiol Ultrasound 52:201–206, 2011.

435. Naude SH, Miller DB: Magnetic resonance imaging findings of a metastatic chemodectoma in
a dog, J S Afr Vet Assoc 77:155–159, 2006.

436. Nolan MW, Arkans MM, LaVine D, et al.: Pilot study to determine the feasibility of radiation
therapy for dogs with right atrial masses and hemorrhagic pericardial effusion, J Vet Cardiol
19:132– 143, 2017.
437. Keene BW, Rush JE, Cooley AJ, et al.: Primary left ventricular hemangiosarcoma diagnosed
by endomyocardial biopsy in a dog, J Am Vet Med Assoc 197:1501–1503, 1990.

438. Sisson D, Thomas WP, Ruehl WW, et al.: Diagnostic value of pericardial fluid analysis in the
dog, J Am Vet Med Assoc 184:51–55, 1984.

439. Fine DM, Tobias AH, Jacob KA: Use of pericardial fluid pH to distinguish between idiopathic
and neoplastic effusions, J Vet Intern Med 17:525–529, 2003.

440. de Laforcade AM, Freeman LM, Rozanski EA, et al.: Biochemical analysis of pericardial fluid
and whole blood in dogs with pericardial effusion, J Vet Intern Med 19:833–836, 2005.

441. Cagle LA, Epstein SE, Owens SD, et al.: Diagnostic yield of cytologic analysis of pericardial
effusion in dogs, J Vet Intern Med 28:66–71, 2014.

442. Shaw SP, Rozanski EA, Rush JE: Cardiac troponins I and T in dogs with pericardial effusion,
J Vet Intern Med 18:322–324, 2004.

443. Chun R, Kellihan HB, Henik RA, et al.: Comparison of plasma cardiac troponin I concentrations
among dogs with cardiac hemangiosarcoma, noncardiac hemangiosarcoma, other neoplasms, and
pericardial effusion of nonhemangiosarcoma origin, J Am Vet Med Assoc 237:806–811, 2010.

444. Boston SE, Higginson G, Monteith G: Concurrent splenic and right atrial mass at presentation
in dogs with hemangiosarcoma: a retrospective study, J Am An Hosp Assoc 47:336–341, 2011.

445. Waters DJ, Caywood DD, Hayden DW, et al.: Metastatic pattern in dogs with splenic
haemangiosarcoma: clinical implications, J Small Anim Pract 29:805–814, 1988.

446. Chow N-H, Chan S-H, Tzai T-S, et al.: Expression profiles of ErbB family receptors and
prognosis in primary transitional cell carcinoma of the urinary bladder, Clin Cancer Research
7:1957–1962, 2001.

447. Taylor S, Rozanski E, Sato AF, et al.: Vascular stent placement for palliation of mass-
associated chylothorax in two dogs, J Am Vet Med Assoc 251:696–701, 2017.

448. Wykes PM, Rouse GP, Orton EC: Removal of five canine cardiac tumors using a stapling
instrument, Vet Surg 15:103–106, 1986.

449. Ogilvie GK, Powers BE, Mallinckrodt CH, et al.: Surgery and doxorubicin in dogs with
hemangiosarcoma, J Vet Intern Med 10:379–384, 1996.

450. Verbeke F, Binst D, Stegen L, et al.: Total venous inflow occlusion and pericardial auto-graft
reconstruction for right atrial hemangiosarcoma resection in a dog, Can Vet J 53:1114–1118, 2012.

451. Morges M, Worley DR, Withrow SJ, et al.: Pericardial free patch grafting as a rescue technique
in surgical management of right atrial HSA, J Am Anim Hosp Assoc 47:224–228, 2011.

452. Crumbaker DM, Rooney MB, Case JB: Thoracoscopic subtotal pericardiectomy and right atrial
mass resection in a dog, J Am Vet Med Assoc 237:551–554, 2010.

453. Buchanan JW, Boggs LS, Dewan S, et al.: Left atrial paraganglioma in a dog:
echocardiography, surgery, and scintigraphy, J Vet Intern Med 12:109–115, 1998.

454. Dunning D, Monnet E, Orton EC, et al.: Analysis of prognostic indicators for dogs with
pericardial effusion: 46 cases (1985-1996), J Am Vet Med Assoc 212:1276–1280, 1998.
455. Case JB, Maxwell M, Aman A, et al.: Outcome evaluation of a thoracoscopic pericardial
window procedure or subtotal pericardectomy via thoracotomy for the treatment of pericardial
effusion in dogs, J Am Vet Med Assoc 242:493–498, 2013.

456. Atencia S, Doyle RS, Whitley NT: Thoracoscopic pericardial window for management of
pericardial effusion in 15 dogs, J Small Anim Pract 54:564–569, 2013.

457. Ployart S, Libermann S, Doran I, et al.: Thoracoscopic resection of right auricular masses in
dogs: 9 cases (2003–2011), J Am Vet Med Assoc 242:237–241, 2012.

458. Mullin CM, Arkans MA, Sammarco CD, et al.: Doxorubicin chemotherapy for presumptive
cardiac hemangiosarcoma in dogs, Vet Comp Oncol 14:e171–e183, 2016.

459. Ghaffari S, Pelio DC, Lange AJ, et al.: A retrospective evaluation of doxorubicin-based
chemotherapy for dogs with right atrial masses and pericardial effusion, J Small Anim Pract 55:254–
257, 2014.

460. Pellin MA, Wouda RM, Robinson K, et al.: Safety evaluation of combination doxorubicin and
toceranib phosphate (Palladia®) in tumour bearing dogs: a phase I dose‐finding study, Vet Comp
Oncol 15:919–931, 2016.

461. de Madron E, Helfand SC, Stebbins KE: Use of chemotherapy for treatment of cardiac
hemangiosarcoma in a dog, J Am Vet Med Assoc 190:887–891, 1987.

462. Murphy LA, Panek CM, Bianco D, et al.: Use of Yunnan Baiyao and epsilon aminocaproic acid
in dogs with right atrial masses and pericardial effusion, J Vet Emerg Crit Care 27:121–126, 2017.

463. McQuown B, Arteaga T, Cunningham S, et al.: Palladia (toceranib phosphate) in the treatment
of heart base tumors, Vet Cancer Soc Ann Conf, 2014.

464. Obradovich JE, Withrow SJ, Powers BE, et al.: Carotid body tumors in the dog eleven cases
(1978–1988), J Vet Intern Med 6:96–101, 1992.

465. Kelsey KL, Kubicek LN, Bacon NJ, et al.: Neuromuscular blockade and inspiratory breath hold
during stereotactic body radiation therapy for treatment of heart base tumors in four dogs, J Am Vet
Med Assoc 250:199–204, 2017.

466. Reynen K: Frequency of primary tumors of the heart, Am J Cardiol 77:107, 1996.

467. Lam KY, Dickens P, Chan AC: Tumors of the heart. A 20-year experience with a review of
12,485 consecutive autopsies, Arch Pathol Lab Med 117:1027–1031, 1993.

468. McAllister HA, Hall RJ, Cooley DA: Tumors of the heart and pericardium, Curr Probl Cardiol
24:59–116, 1999.

469. Shapiro LM: Cardiac tumours: diagnosis and management, Heart 85:218–222, 2001.

470. Jóźwiak S, Kotulska K, Kasprzyk-Obara J, et al.: Clinical and genotype studies of cardiac
tumors in 154 patients with tuberous sclerosis complex, Pediatrics 118:e1146–e1151, 2006.

471. Sciacca P, Giacchi V, Mattia C, et al.: Rhabdomyomas and tuberous sclerosis complex: our
experience in 33 cases, BMC Cardiovasc Disord 14, 66–66, 2014.

472. Saad AM, Abushouk AI, Al-Husseini MJ, et al.: Characteristics, survival and incidence rates
and trends of primary cardiac malignancies in the United States, Cardiovasc Pathol 33:27–31,
2018.
473. Ramlawi B, Leja MJ, Abu Saleh WK, et al.: Surgical treatment of primary cardiac sarcomas:
review of a single-institution experience, Ann Thorac Surg 101:698–702, 2016.

474. Bakaeen FG, Reardon MJ, Coselli JS, et al.: Surgical outcome in 85 patients with primary
cardiac tumors, Am J Surg 186:641–647, 2003.

475. Llombart-Cussac A, Pivot X, Contesso G, et al.: Adjuvant chemotherapy for primary cardiac
sarcomas: the IGR experience, Br J Cancer 78:1624–1628, 1998.

476. Abu Saleh WK, Ramlawi B, Shapira OM, et al.: Improved outcomes with the evolution of a
neoadjuvant chemotherapy approach to right heart sarcoma, Ann Thorac Surg 104:90–96, 2017.

477. Bussani R, De‐Giorgio F, Abbate A, et al.: Cardiac metastases, J Clin Pathol 60:27–34, 2007.

478. Moore PF: A review of histiocytic diseases in dogs and cats, Vet Pathol 51:167–184, 2014.

479. Affolter VK, Moore PF: Canine cutaneous and systemic histiocytosis of dermal and dendritic
origin, Am J Dermatopathol 22:40–48, 2000.

480. Affolter VK, Moore PF: Localized and disseminated histiocytic sarcoma of dendritic cell origin
in dogs, Vet Pathol 39:74–83, 2002.

481. Moore PF, Affolter V, Olivry T, et al.: The use of immunological reagents in defining the
pathogenesis of canine skin disease involving proliferation of leukocytes. In Kwochka KW, Wilemse
T, von Tscharner C, editors: Advances in veterinary dermatology, Oxford, 1998, Butterworth-
Heinemann, pp 77–94.

482. Moore PF, Schrenzel MD, Affolter VK, et al.: Canine cutaneous histiocytoma is an
epidermotropic Langerhans cell histiocytosis that expresses CD1 and specific beta 2-integrin
molecules, Am J Pathol 148:1699–1708, 1996.

483. Moore PF, Affolter VK, Vernau W, et al.: Canine hemophagocytic histiocytic sarcoma: a
proliferative disorder of CD11d+ macrophages, Vet Pathol 43:632–645, 2006.

484. Shortman K, Naik SH: Steady-state and inflammatory dendriticcell development, Nat Rev
Immunol 7:19–30, 2007.

485. Larregina at, Morelli AE, Spencer LA, et al.: Dermal-resident CD14+ cells differentiate into
Langerhans cells, Nat Immunol 2:1151–1158, 2001.

486. Shortman K, Caux C: Dendritic cell development: multiple pathways to nature’s adjuvants,
Stem Cells 15:409–419, 1997.

487. Shortman K, Liu YJ: Mouse and human dendritic cell subtypes, Nat Rev Immunol 2:151–161,
2002.

488. Ricklin ME, Roosje P, Summerfield A: Characterization of canine dendritic cells in healthy,
atopic, and non-allergic inflamed skin, J Clin Immunol 30:845–854, 2010.

489. Zaba LC, Krueger JG, Lowes MA: Resident and “inflammatory” dendritic cells in human skin, J
Invest Dermatol 129:302–308, 2009.

490. Looringh van Beeck FA, Zajonc DM, Moore PF, et al.: Two canine CD1a proteins are
differentially expressed in skin, Immunogenetics 60:315–324, 2008.

491. Danilenko DM, Moore PF, Rossitto PV: Canine leukocyte cell adhesion molecules (LeuCAMS):
characterization of the CD11/CD18 family, Tiss Antig 40:13–21, 1992.
492. Danilenko DM, Rossitti PV, Van der Vieren M, et al.: A novel canine leukointegrin, alpha d beta
2, is expressed by specific macrophage subpopulations in tissue and a minor CD8+ lymphocyte
subpopulation in peripheral blood, J Immunol 155:35–44, 1995.

493. Ricklin ME, Roosje P, Summerfield A: Characterization of canine dendritic cells in healthy,
atopic, and non-allergic inflamed skin, J Clin Immunol 30:845–854, 2010.

494. Scalapino KJ, Daikh DI: CTLA-4: a key regulatory point in the control of autoimmune disease,
Immunol Rev 223:143–155, 2008.

495. Banchereau J, Steinman RM: Dendritic cells and the control of immunity, Nature 392:245–252,
1998.

496. Banchereau J, Briere F, Caux C, et al.: Immunology of dendritic cells, Ann Rev Immunol
18:767–811, 2000.

497. Swerdlow SH, Campo E, et al.: WHO classification of tumors of the haematopoietic and
lymphoid tissues, Lyon, 2008, International Agency for Research on Cancer (IARC).

498. Valli VEO: Histological classification of hematopoietic tumors of domestic animals. In Valli
VEO, R Jacobs RM, et al.: World health organization international histological classification of
tumors of domestic animals, Washington, D.C., 2002, Armed Forces Institute of Pathology,
American Registry of Pathology.

499. Kato Y, Murakami M, Hoshino Y, et al.: The class A macrophage scavenger receptor CD204 is
a useful immunohistochemical marker of canine histiocytic sarcoma, J Comp Pathol 148:188–196,
2013.

500. Marquet FM, Bonneau F, Pascale C, et al.: Characterization of dendritic cells subpopulations
in skin and afferent lymph in the swine model, PLoS One 6:e16320, 2011.

501. Yi H, Guo C, Yu X, et al.: Targeting the immunoregulator SRA/CD204 potentiates specific

dendritic cell vaccine-induced T-cell response and antitumor immunity, Cancer Res 71:6611–6620,
2011.

502. Ide T, Uchida K, Kagawa Y, et al.: Pathological and immunohistochemical features of subdural
histiocytic sarcomas in 15 dogs, J Vet Diagn Invest 23:127–132, 2011.

503. Schmidt JM, North SM, Freeman KP, et al.: Canine paediatric oncology: retrospective
assessment of 9522 tumours in dogs up to 12 months (1993-2008), Vet Comp Oncol 8:283–292,
2010.

504. Glick AD, Holscher M, Campbell GR: Canine cutaneous histiocytoma: ultrastructural and
cytochemical observations, Vet Pathol 13:374–380, 1976.

505. Kelly DF: Canine cutaneous histiocytoma. A light and microscopic study, Vet Pathol 7:12–27,
1970.

506. Bostock DE: Neoplasms of the skin and subcutaneous tissues in dogs and cats, Br Vet J
142:1–19, 1986.

507. Rothwell TLW, Howlett CR, Middleton DJ, et al.: Skin neoplasms of dogs in Sydney, Aust Vet J
64:161–164, 1987.

508. Gross TL, Affolter VK: Advances in skin oncology. In Kwochka KW, Willemse T, von Tscharner
C, editors: Advances in veterinary dermatology, Oxford, UK, 1998, Butterworth-Heinmann, pp 382–
385.
509. Angus JC, de Lorimier LP: Lymphohistiocytic neoplasms. In Campbell KL, editor: Small animal
dermatology secrets, Philadelphia, 2004, Hanley and Belfus, pp 425–442.

510. Ramos-Vara JA, Miller MA: Immunohistochemical expression of E-cadherin does not
distinguish canine cutaneous histiocytoma from other canine round cell tumors, Vet Pathol 48:758–
763, 2011.

511. Baines SJ, McInnes EF, McConnell I: E-cadherin expression in canine cutaneous
histiocytomas, Vet Rec 162:509–513, 2008.

512. Pires I, Queiroga FL, Alves A, Silva F, et al.: Decrease of E-cadherin expression in canine
cutaneous histiocytoma appears to be related to its spontaneous regression, Anticancer Res
29:2713–2717, 2009.

513. Schmitz L, Favara BE: Nosology and pathology of Langerhans cell histiocytosis, Hematol
Oncol Clin North Am 12:221–246, 1998.

514. Munn S, Chu AC: Langerhans cell histiocytosis of the skin, Hematol Oncol Clin North Am
12:269–286, 1998.

515. Maina E, Colombo S, Stefanello D: Multiple cutaneous histiocytomas treated with lomustine in
a dog, Vet Dermatol 25:559–599, 2014.

516. Nagata M, Hirata M, Ishida T, et al.: Progressive Langerhans’ cell histiocytosis in a puppy, Vet
Dermatol 11:241–246, 2000.

517. Faller M, Lamm C, Affolter VK, et al.: Retrospective characterisation of solitary cutaneous
histiocytoma with lymph node metástasis in eight dogs, J Small Anim Pract 57:548–552, 2016.

518. Mays MB, Bergeron JA: Cutaneous histiocytosis in dogs, J Am Vet Med Assoc 188:377–381,
1986.

519. Palmeiro BS, Morris DO, Goldschmidt MH, et al.: Cutaneous reactive histiocytosis in dogs: a
retrospective evaluation of 32 cases, Vet Dermatol 18:332–340, 2007.

520. Scott DW, Angurano DK, Suter MM: Systemic histiocytosis in 2 dogs, Canine Pract 14:7–12,
1987.

521. Moore PF: Systemic histiocytosis of Bernese mountain dogs, Vet Pathol 21:554–563, 1984.

522. Scott DW, Miller WH, Griffin CE: Lymphohistiocytic neoplasms. Muller and Kirk’s small animal
dermatology, Philadelphia, 2000, WB Saunders, pp 1130–1357.

523. Scherlie PH, Smedes SL, Feltz T, et al.: Ocular manifestations of systemic histiocytosis in a
dog, J Am Vet Med Assoc 201:1229, 1992.

524. DeHeer HL, Grindem CB: Histiocytic disorders. In Jaim NC, editor: Schalm’s veterinary
hematology, ed 4, Philadelphia, 1986, Lea & Febiger, pp 696–702.

525. Moore PF: Malignant histiocytosis of Bernese mountain dogs, Vet Pathol 23:1–10, 1986.

526. Rosin A, Moore P, Dubielzig R: Malignant histiocytosis in Bernese mountain dogs, J Am Vet
Med Assoc 188:1041–1045, 1986.

527. Lenz JA, Furrow E, Craig LE, et al.: Histiocytic sarcoma in 14 miniature schnauzers-a new
breed predisposition? J Small Anim Pract 58:461–467, 2017.

528. Takahashi M, Tomiyasu H, Hotta E, et al.: Clinical characteristics and prognostic factors in
dogs with histiocytic sarcomas in Japan, J Vet Med Sci 76:661–666, 2014.
529. Voegeli E, Welle M, Hauser B, et al.: Histiocytic sarcoma in the Swiss population of Bernese
mountain dogs: a retrospective study of its genetic predisposition, Schweiz Arch Tierheilkd
148:281–288, 2006.

530. Hedan B, Thomas R, Motsinger-Reif A, et al.: Molecular cytogenetic characterization of canine

histiocytic sarcoma: a spontaneous model for human histiocytic cancer identifies deletion of tumor
suppressor genes and highlights influence of genetic background on tumor behaviour, BMC Cancer
11:201, 2011.

531. Shearin AL, Hedan B, Cadieu E, et al.: The MTAP-CDKN2A locus confers susceptibility to a
naturally occurring canine cancer, Cancer Epidemiol Biomarkers Prev 21:1019–1027, 2012.

532. Thaiwong T, Sirivisoot S, Takada M, et al.: Gain-of-function mutation in PTPN11 in histiocytic

sarcomas of Bernese mountain dogs, Vet Comp Oncol 16:220–228, 2018.

533. Manor EK, Craig LE, Sun X, et al.: Prior joint disease is associated with increased risk of
periarticular histiocytic sarcoma in dogs, Vet Comp Oncol 16:E83–E88, 2018.

534. van Kuijk L, van Ginkel K, de Vos JP, et al.: Peri-articular histiocytic sarcoma and previous
joint disease in Bernese mountain dogs, J Vet Intern Med 27:293–299, 2013.

535. Constantino-Casas F, Mayhew D, Hoather TM, et al.: The clinical presentation and
histopathologic–immunohistochemical classification of histiocytic sarcomas in the flat coated
retriever, Vet Pathol 48:764–771, 2011.

536. Erich SA, Constantino-Casas F, Dobson JM, et al.: Morphological distinction of histiocytic
sarcoma from other tumor types in Bernese mountain dogs and flatcoated retrievers, Vivo 32:7–17,
2018.

537. Dobson J, Hoather T, McKinley TJ, et al.: Mortality in a cohort of flat-coated retrievers in the
UK, Vet Comp Oncol 7:115–121, 2009.

538. Craig LE, Julian ME, Ferracone JD: The diagnosis and prognosis of synovial tumors in dogs:
35 cases, Vet Pathol 39:66–73, 2002.

539. Hayden DW, Waters DJ, Burke BA, et al.: Disseminated malignant histiocytosis in a golden
retriever: clinicopathologic, ultrastructural, and immunohistochemical findings, Vet Pathol 30:256–
264, 1993.

540. Kohn B, Arnold P, Kaser-Hotz B, et al.: Malignant histiocytosis of the dog: 26 cases (1989-
1992), Kleintierpraxis 38:409–424, 1993.

541. Fant P, Caldin M, Furlanello T, et al.: Primary gastric histiocytic sarcoma in a dog—a case
report, J Vet Med 51:358–362, 2004.

542. Skorupski K, Clifford C, Paoloni M, et al.: CCNU for the treatment of dogs with histiocytic
sarcoma, J Vet Int Med 21:121–126, 2007.

543. Naranjo C, Dubielzig R, Friedrichs K: Canine ocular histiocytic sarcoma, Vet Ophthalmol
10:179–185, 2007.

544. Vernau KM, Higgins RJ, Bollen AW, et al.: Primary canine and feline nervous system tumors:
intraoperative diagnosis using the smear technique, Vet Pathol 38:47–57, 2001.

545. Snyder J, Lipitz L, Skorupski K, et al.: Secondary intracranial neoplasia in the dog: 177 cases
(1986-2003), J Vet Intern Med 22:172– 177, 2008.
546. Mariani CL, Jennings MK, Olby NJ, et al.: Histiocytic sarcoma with central nervous system
involvement in dogs: 19 Cases (2006– 2012), J Vet Intern Med 29:607–613, 2015.

547. Brown DE, Thrall MA, Getzy DM, et al.: Cytology of canine malignant histiocytosis, Vet Clin
Pathol 23:118–123, 1994.

548. Kato Y, Funato R, Hirata A, et al.: Immunocytochemical detection of the class A macrophage
scavenger receptor CD204 using airdried cytologic smears of canine histiocytic sarcoma, Vet Clin
Pathol 43:589–593, 2014.

549. Pierezan F, Mansell J, Ambrus A, et al.: Immunohistochemical expression of ionized calcium

binding adapter molecule 1 in cutaneous histiocytic proliferative, neoplastic, and inflammatory
disorders of dogs and cats, J Comp Pathol 151:347–351, 2014.

550. The CADETSM HM assay. 2018. Retrieved from: https://www.sentinelbiomedical.com/cadet-

hm-for-vets/

551. Weiss DJ, Evanson OA, Sykes J: A retrospective study of canine pancytopenia, Vet Clin
Pathol 28:83–88, 1999.

552. Newlands CE, Houston DM, Vasconcelos DY: Hyperferritinemia associated with malignant
histiocytosis in a dog, J Am Vet Med Assoc 205:849–851, 1994.

553. Friedrichs K, Thomas C, Plier M, et al.: Evaluation of serum ferritin as a tumor marker for
canine histiocytic sarcoma, J Vet Intern Med 24:904–911, 2010.

554. Nielsen LN, McEvoy F, Jessen LR, et al.: Investigation of a screening programme and the
possible identification of biomarkers for early disseminated histiocytic sarcoma in Bernese mountain
dogs, Vet Comp Oncol 10:124–134, 2012.

555. Tsai S, Sutherland-Smith, Burgess K, et al.: Imaging characteristics of intrathoracic histiocytic

sarcoma in dogs, Vet Radiol Ultrasound 53:21–27, 2012.

556. Barrett LE, Pollard RE, Zwingenberger A, et al.: Radiographic characterization of primary lung
tumors in 74 dogs, Vet Radiol Ultrasound 55:480–487, 2014.

557. Cruz-Arambulo R, Wrigley R, Powers B: Sonographic features of histiocytic neoplasms in the

canine abdomen, Vet Radiol Ultrasound 45:554–558, 2004.

558. Weiss DJ: Flow cytometric evaluation of hemophagocytic disorders in canine, Vet Clin Pathol
31:36–41, 2001.

559. Klahn SL, Kitchell B, Dervisis N: Evaluation and comparison of outcomes in dogs with
periarticular and nonperiarticular histiocytic sarcoma, J Am Vet Met Assoc 239:90–96, 2001.

560. Skorupski K, Rodriguez C, Krick E, et al.: Long-term survival in dogs with localized histiocytic
sarcoma treated with CCNU as an adjuvant to local therapy, Vet Comp Oncol 7:139–144, 2009.

561. Rassnick K, Moore A, Russell D, et al.: Phase II, open-label trial of single-agent CCNU in dogs
with previously untreated histiocytic sarcoma, J Vet Intern Med 24:1528–1531, 2010.

562. Cannon C, Borgatti A, Henson M, et al.: Evaluation of a combination chemotherapy protocol

including lomustine and doxorubicin in canine histiocytic sarcoma, J Sm Anim Pract 56:425–429,
2015.

563. Kezer KA, Barber LG, Jennings SH: Efficacy of dacarbazine as a rescue agent for histiocytic
sarcoma in dogs, Vet Comp Oncol 16:77–80, 2018.
564. Mason SL, Finotello R, Blackwood L: Epirubicin in the treatment of canine histiocytic sarcoma:
sequential, alternating and rescue chemotherapy, Vet Comp Oncol 16:E30–E37, 2018.

565. Vail DM, Kravis LD, Cooley AJ, et al.: Preclinical trial of doxorubicin entrapped in sterically
stabilized liposomes in dogs with spontaneously arising malignant tumors, Cancer Chemother
Pharmacol 39:410–416, 1997.

566. Poirier VJ, Hershey AE, Burgess KE, et al.: Efficacy and toxicity of paclitaxel (Taxol) for the
treatment of canine malignant tumors, J Vet Intern Med 18:219–222, 2004.

567. Uno Y, Momio Y, Watari T, et al.: Malignant histiocytosis with multiple skin lesions in a dog, J
Vet Med Sci 55:1059–1061, 1993.

568. Tripp CD, Fidel J, Anderson CL, et al.: Tolerability of metronomic administration of lomustine in
dogs with cancer, J Vet Intern Med 25:278–284, 2011.

569. Leach TN, Childress MO, Greene SN, et al.: Prospective trial of metronomic chlorambucil
chemotherapy in dogs with naturally occurring cancer, Vet Comp Oncol 10:102–112, 2011.

570. Hafeman S, London C, Elmslie R, et al.: Evaluation of liposomal clodronate for treatment of
malignant histiocytosis in dogs, Cancer Immunol Immunother 59:441–452, 2010.

571. Fidel J, Schiller I, Hauser Y, et al.: Histiocytic sarcomas in flatcoated retrievers: a summary of
37 cases (November 1998-March 2005), Vet Comp Oncol 4:63–74, 2006.

572. Friedrichs K, Young K: Histiocytic sarcoma of macrophage origin in a cat: case report with a
literature review of feline histiocytic malignancies and comparison with canine hemophagocytic
histiocytic sarcoma, Vet Clin Pathol 37:121–128, 2008.

573. Walton RM, Brown DE, Burkhard MJ, et al.: Malignant histiocytosis in a domestic cat:
cytomorphologic and immunohistochemical features, Vet Clin Pathol 26:56–60, 1997.

574. Kraje AC, Patton CS, Edwards DF: Malignant histiocytosis in 3 cats, J Vet Intern Med 15:252–
256, 2001.

575. Smoliga J, Schatzberg S, Peters J, et al.: Myelopathy caused by a histiocytic sarcoma in a cat,
J Small Anim Pract 46:34–38, 2005.

576. Bell R, Philbey A, Martineau H, et al.: Dynamic tracheal collapse associated with disseminated
histiocytic sarcoma in a cat, J Small Anim Pract 47: 461-464, 2006.

577. Court E, Earnest-Koons K, Barr S, et al.: Malignant histiocytosis in a cat, J Am Vet Med Assoc
203:1300–1302, 1993.

578. Ide T, Uchida K, Tamura S, et al.: Histiocytic sarcoma in the brain of a cat, J Vet Med Sci
72:99–102, 2010.

579. Ide K, Setoguchi-Mukai A, Nakagawa T, et al.: Disseminated histiocytic sarcoma with

excessive hemophagocytosis in a cat, J Vet Med Sci 71:817–820, 2009.

580. Pinard J, Wagg C, Girard C, et al.: Histiocytic sarcoma in the tarsus of a cat, Vet Pathol
43:1014–1017, 2006.

581. Treggiari E, Ressel L, Polton GA, et al.: Clinical outcome, PDGFRB and KIT expression in
feline histiocytic disorders: a multicentre study, Vet Comp Oncol 15:65–77, 2017.

582. Affolter V, Moore P: Feline progressive histiocytosis, Vet Pathol 43:646–655, 2006.
583. Busch M, Reilly C, Luff J, et al.: Feline pulmonary Langerhans cell histiocytosis with multiorgan
involvement, Vet Pathol 45:816–824, 2008.

584. Jaffe ES: Histiocytic and dendritic cell neoplasms. In Jaffe ES, Harris HL, Stein H, et al.: World
Health Organization classification of tumors: pathology and genetics of tumors of haematopoietic
and lymphoid tissues, 2001, pp 275–288.

585. Shimono J, Miyoshi H, Arakawa F, et al.: Prognostic factors for histiocytic and dendritic cell
neoplasms, Oncotarget 19:98723–98732, 2017.

586. Ozkaya N, Dogan A, Abdel-Wahab O: Identification and targeting of kinase alterations in

histiocytic neoplasms, Hematol Oncol Clin North Am 31:705–719, 2017.